WO2013118823A1 - セレウリドおよびその誘導体の製造方法、セレウリド製造の為の中間体ならびにセレウリド誘導体 - Google Patents
セレウリドおよびその誘導体の製造方法、セレウリド製造の為の中間体ならびにセレウリド誘導体 Download PDFInfo
- Publication number
- WO2013118823A1 WO2013118823A1 PCT/JP2013/052870 JP2013052870W WO2013118823A1 WO 2013118823 A1 WO2013118823 A1 WO 2013118823A1 JP 2013052870 W JP2013052870 W JP 2013052870W WO 2013118823 A1 WO2013118823 A1 WO 2013118823A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cereulide
- nmr
- mmol
- cdcl
- reaction
- Prior art date
Links
- JWWAHGUHYLWQCQ-UHFFFAOYSA-N cereulide Chemical compound CC(C)CC1OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C)NC(=O)C(CC(C)C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C)NC(=O)C(CC(C)C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C)NC1=O JWWAHGUHYLWQCQ-UHFFFAOYSA-N 0.000 title claims abstract description 137
- 108010061320 cereulide Proteins 0.000 title claims abstract description 61
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 18
- 239000002243 precursor Substances 0.000 claims abstract description 13
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 13
- 108010002156 Depsipeptides Proteins 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 238000010976 amide bond formation reaction Methods 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 123
- 229910052739 hydrogen Inorganic materials 0.000 description 99
- 239000000243 solution Substances 0.000 description 86
- 238000006243 chemical reaction Methods 0.000 description 71
- 238000004809 thin layer chromatography Methods 0.000 description 66
- 238000005160 1H NMR spectroscopy Methods 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 51
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 38
- 238000003786 synthesis reaction Methods 0.000 description 38
- 238000001816 cooling Methods 0.000 description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 29
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
- 229960004295 valine Drugs 0.000 description 23
- 239000012044 organic layer Substances 0.000 description 22
- 238000000746 purification Methods 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 229960002989 glutamic acid Drugs 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- 238000010898 silica gel chromatography Methods 0.000 description 16
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 15
- -1 diethylphosphoryl Chemical group 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- 235000017557 sodium bicarbonate Nutrition 0.000 description 15
- 239000012230 colorless oil Substances 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 12
- 229930182819 D-leucine Natural products 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 10
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000004474 valine Substances 0.000 description 9
- 0 CC(C)C[C@@](C(O)=O)OC([C@](*)N)=O Chemical compound CC(C)C[C@@](C(O)=O)OC([C@](*)N)=O 0.000 description 8
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 8
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 150000001261 hydroxy acids Chemical class 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 229940070710 valerate Drugs 0.000 description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 229960002684 aminocaproic acid Drugs 0.000 description 5
- XANDRLFOMIFEFY-NSHDSACASA-N benzyl (2s)-2-hydroxy-3-methylbutanoate Chemical compound CC(C)[C@H](O)C(=O)OCC1=CC=CC=C1 XANDRLFOMIFEFY-NSHDSACASA-N 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- QVHJQCGUWFKTSE-RXMQYKEDSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 241000193755 Bacillus cereus Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- NGEWQZIDQIYUNV-BYPYZUCNSA-N (S)-2-hydroxy-3-methylbutyric acid Chemical compound CC(C)[C@H](O)C(O)=O NGEWQZIDQIYUNV-BYPYZUCNSA-N 0.000 description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 3
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 3
- 206010016952 Food poisoning Diseases 0.000 description 3
- 208000019331 Foodborne disease Diseases 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 150000008539 L-glutamic acids Chemical class 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- LNYCLASVFGVAII-GFCCVEGCSA-N benzyl (2r)-2-hydroxy-4-methylpentanoate Chemical compound CC(C)C[C@@H](O)C(=O)OCC1=CC=CC=C1 LNYCLASVFGVAII-GFCCVEGCSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- JXHBSPWXNWZNDR-MRVPVSSYSA-N tert-butyl (2r)-2-hydroxy-4-methylpentanoate Chemical compound CC(C)C[C@@H](O)C(=O)OC(C)(C)C JXHBSPWXNWZNDR-MRVPVSSYSA-N 0.000 description 2
- XQTIFSCLEWPKCF-ZETCQYMHSA-N tert-butyl (2s)-2-hydroxy-3-methylbutanoate Chemical compound CC(C)[C@H](O)C(=O)OC(C)(C)C XQTIFSCLEWPKCF-ZETCQYMHSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- TYRGLVWXHJRKMT-MRVPVSSYSA-N (2r)-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)OCC1=CC=CC=C1 TYRGLVWXHJRKMT-MRVPVSSYSA-N 0.000 description 1
- QVAQMUAKTNUNLN-LURJTMIESA-N (4s)-4-amino-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)[C@@H](N)CCC(O)=O QVAQMUAKTNUNLN-LURJTMIESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JVLRBIADOALMLB-UHFFFAOYSA-N 2-ethoxy-1,2-dihydroquinoline Chemical compound C1=CC=C2C=CC(OCC)NC2=C1 JVLRBIADOALMLB-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 150000007567 36-membered macrocycles Chemical class 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
- 229930182831 D-valine Natural products 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- QGRKRNTWXGGAOU-UHFFFAOYSA-N benzotriazol-1-yloxyphosphane Chemical compound C1=CC=C2N(OP)N=NC2=C1 QGRKRNTWXGGAOU-UHFFFAOYSA-N 0.000 description 1
- HTJFVAIXONBPGF-UHFFFAOYSA-N benzyl 6-aminohexanoate Chemical compound NCCCCCC(=O)OCC1=CC=CC=C1 HTJFVAIXONBPGF-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- GZVVNAWGGPWOOK-UHFFFAOYSA-N ethyl 2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OCC)CC=CC2=C1 GZVVNAWGGPWOOK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- HBEJJYHFTZDAHZ-MRVPVSSYSA-N tert-butyl (2r)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@@H](N)C(=O)OC(C)(C)C HBEJJYHFTZDAHZ-MRVPVSSYSA-N 0.000 description 1
- BFNYNEMRWHFIMR-UHFFFAOYSA-N tert-butyl 2-cyanoacetate Chemical compound CC(C)(C)OC(=O)CC#N BFNYNEMRWHFIMR-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
Definitions
- the present invention relates to a process for the preparation of cereulide and its derivatives.
- the invention also relates to intermediates and cereulide derivatives for the preparation of cereulide.
- Bacillus cereus bacteria which inhabit the soil propagate in starch-based foods such as rice, pilaf and spaghetti to produce cereuride which causes vomiting action to animals such as humans. It is also known that not all Bacillus cereus produce cereulide, but only Bacillus cereus which has acquired the cereulide synthetic gene produces this toxic substance.
- Such cereulide is known to be highly heat resistant, acid resistant and digestive enzyme resistant, not inactivated in the process of cooking and digestion, and acting on the small intestinal nervous system to induce the vomiting phenomenon,
- liver damage, mitochondrial toxicity, induction of morphological change of cells, induction of apoptosis, etc. have been reported, but molecular studies on the molecular mechanism of the vomiting phenomenon and other toxicities have not progressed.
- Patent Documents 1 and 2 For the determination of food poisoning etc., methods based on the detection of a synthetase gene in a sample have also been proposed (Patent Documents 1 and 2).
- cereulide standard products are often required for qualitative or quantitative analysis for the determination of food poisoning by cereulide, and for elucidation of toxicity evaluation or mechanism at the cellular or molecular level.
- Currently commercially available cereulide is extracted from the culture solution of Bacillus cereus and is available as a methanol solution.
- Non-Patent Documents 1 and 2 As a method of obtaining such cereulide, a method of synthesizing cereulide and a derivative thereof has also been proposed (Non-Patent Documents 1 and 2).
- Cereulide which is currently marketed, is very expensive and is not very high in purity because it is derived from a culture solution. It is desirable to easily produce high purity cereulide.
- an object of the present invention is to provide a method for producing cereulide and a derivative thereof, and a cereulide derivative.
- the present invention has the following formula: and (Wherein Y represents OH or NH (CH 2 ) 5 COOH) A precursor of cereulide or a derivative thereof selected from the group consisting of
- the invention further provides: Or (Wherein X represents isopropyl, (CH 2 ) 2 COOH, or (CH 2 ) 2 CONH (CH 2 ) 5 COOH).
- the present invention further provides the following depsipeptides: (Where l is an integer of 0 to 2, n is an integer of 0 to 2, m is an integer of 0 or 1, where l, m and n do not simultaneously become 0, l + m + n is 2 The following).
- the invention further provides: (Here, X represents isopropyl, (CH 2 ) 2 COOH, or (CH 2 ) 2 CONH (CH 2 ) 5 COOH)
- the present invention relates to a method for producing cereulide or a derivative thereof as shown in and including a cyclization reaction by intramolecular amide bond formation of a precursor of the above-mentioned cereulide or derivative thereof.
- the above-mentioned production method preferably further comprises the step of preparing the above-mentioned didepsi peptide.
- the above manufacturing method it is preferable to include the step of preparing a depsipeptide of
- the invention further provides the following formula: (Wherein R represents (CH 2 ) 2 COOH or (CH 2 ) 2 CONH (CH 2 ) 5 COOH).
- the method for producing cereulide of the present invention and a derivative thereof it is possible to easily obtain high purity cereulide or a derivative thereof. Furthermore, the cereulide derivative of the present invention is useful for preparation of an antibody for detecting cereulide.
- FIG. 2 shows the 1 H-NMR (CDCl 3 ) spectrum of the octadepsipeptide of this invention.
- FIG. 2 shows the 1 H-NMR (CDCl 3 ) spectrum of the dodecadepsipeptide of the present invention.
- FIG. 2 shows the 1 H-NMR (CDCl 3 ) spectrum of the dodecadepsipeptide of the present invention.
- FIG. 2 shows the 1 H-NMR (CDCl 3 ) spectrum of the dodecadepsipeptide of the present invention.
- Cereulide is a 36-membered macrocycle (macrolide) in which six amino acids and six hydroxy acids are alternately linked by an amide bond and an ester bond, and can also be called a cyclododecadepsipeptide. Cereulide includes two amino acids, L-valine (L-Val) and D-alanine (D-Ala), and two ⁇ -hydroxy acids, D-leucine (DO-Leu) and L-valine ( It has the following structure composed of LO-Val).
- cereulide acts as an ionophore for K + , Na + , NH 4 + .
- Such scavenging action is also considered to be the cause of biological activity.
- the inventors consider that, in the total synthesis of cereulide, the step of cyclizing a linear precursor to construct a 36-membered ring structure is the most important key step, and in order to achieve this cyclization reaction, It was noted that the method by formation of an ester bond was taken. With respect to cereulide and derivatives, the previously known synthetic methods all include a cyclization step as shown in the schematic below.
- cereulide is a macrolide in which three of the repeating structural units are linked to form a cyclic, and can also be expressed as (L-Val-DO-Leu-D-Ala-LO-Val) 3 .
- the present invention relates to a novel production method in which the construction of a macrocycle by amide bond formation is a key reaction unlike the conventional method.
- Starting materials in the production method of the present invention are all commercially available, and two hydroxy acids, namely D-leucine acid (DO-Leu) and L-valerate (LO-Val) are commercially available D-leucine and L It can be prepared from valine by methods known in the literature and used for subsequent fragment synthesis.
- a tetradepsipeptide of a repeating structural unit is synthesized, and then, two structural units are combined to obtain an octadepsipeptide (2 x structural unit), and then further combined with a tetradepsipeptide to obtain a three structural unit.
- the linear dodecadepsipeptide (precursor) was produced and cyclized.
- the intramolecular cyclization reaction of the precursor by the amide bond construction in the present invention can be performed by changing various reaction conditions such as the condensing agent, the solvent, the temperature, etc., and optimization for achieving a high yield can be achieved. It is.
- cereulide and its derivative synthesis can be determined as a commercially available raw material (amino acid). That is, L-valine, D-leucine, D-alanine can be synthesized for the synthesis of cereulide, and L-glutamic acid and 6-aminohexanoic acid can be added to these for derivative synthesis.
- L-valine can be provided for the synthesis with an optional protecting group, or a commercially available product with the protecting group attached can be used as it is.
- examples of commercially available products include Boc-L-valine protected with a tert-butoxycarbonyl group manufactured by Tokyo Kasei Kogyo Co., Ltd.
- D-leucine acid and L-valerate can be synthesized from D-leucine and L-valine, respectively.
- Any hydroxy acid such as D-leucine acid or L-valerate may be used as long as it can convert the amino group of D-leucine and L-valerate to a hydroxyl group.
- D-leucine or L-valine a method of reacting D-leucine or L-valine with nitrite can be mentioned. Prior to this reaction, it is preferred to use D-leucine or L-valine dissolved in a strong acid such as sulfuric acid or hydrochloric acid.
- the hydroxy acid thus obtained can be protected for protection in preparation for the next reaction.
- a protecting group a benzyl group is preferably used.
- a protective group can be added to D-alanine to prepare for the next reaction.
- the didepsi peptide is synthesized using the amino acid and hydroxy acid thus obtained.
- Didepsi peptide may be synthesized under any conditions that can achieve esterification by dehydration reaction.
- a particularly preferable reaction is a reaction performed by adding a strong base such as dimethylaminopyridine and dicyclohexylcarbodiimide to a solvent such as a dichloromethane solution.
- L-valine with D-leucine acid, and then remove the group protecting the carboxyl group for the next synthesis of tetradepsipeptide.
- D-alanine and D-valerate can be coupled, and then the group protecting the amino group can be removed to be subjected to the synthesis of the next tetradepsipeptide.
- the obtained didepsi peptide is coupled to synthesize tetradepsi peptide.
- any conditions may be used as long as an amide bond can be achieved.
- a method in which various condensing agents are allowed to act under neutral conditions can be adopted.
- the tetradepsipeptide is to be a repeating unit for the synthesis of cereulide, and, for ease of subsequent synthesis, for example, 2 of fragment A and fragment B in which a protecting group is added to each other position of the end It is also desirable to create a type.
- an octadepsipeptide is synthesized by subjecting the fragments thus obtained to an amide bond, and a dodecadepsipeptide is further synthesized.
- the linear dodecadepsipeptide thus obtained is preferably cyclized while preventing an intermolecular reaction to synthesize cereulide.
- the intramolecular cyclization reaction can be efficiently advanced by optimizing various conditions such as a condensing agent, a solvent, and a temperature.
- the condensing agent examples include, but are not limited to, organic phosphorus compounds such as diphenylphosphoryl azide (DPPA), diethylphosphoryl cyanidate, azidotris (dimethylamino) phosphonium hexafluorophosphate, N-ethoxycarbonyl- Quinoline based peptide condensing agent such as 2-ethoxy-1,2-dihydroquinoline (EEDQ), 1-isobutyl-2-isobutyl-1,2-dihydroxyquinoline, O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate (HATU), O- (benzotriazol-1-yl) -N, N, N', N'-tetramethyluronium hexafluoro Uronium condensation agents such as phosphate (HBTU), diisopropyl carbodiimide (DIC), dicyclo
- the reaction solvent used at this time includes methylene chloride, dimethylformamide and the like.
- the intramolecular reaction takes precedence over the intermolecular reaction, and it is possible to increase the isolation yield of the desired product. That is, it is preferable to suppress the formation of by-products and give priority to the intramolecular cyclization reaction.
- the invention further has high applicability to the synthesis of derivatives of cereulide. That is, by appropriately changing the constituent amino acid or hydroxy acid in the repeating structural unit, simple derivative synthesis can be performed.
- novel derivative syntheses can be performed, such as E-celeurid in which L-valine is replaced by L-glutamic acid, and EAHA-celeurid in which aminohexanoic acid is introduced into E-sereulide.
- E-serouride is a derivative in which one L-valine in cereurido is replaced with L-glutamic acid
- EAHA-serouride is one in which the omega carboxyl group of E-seleuride is modified with aminohexanoic acid.
- These two derivatives have a reactive carboxyl group disposed via a carbon chain outside the 36-membered ring, which can be further chemically modified and can be used as a hapten molecule or a labeling molecule for producing an anti-cereulide antibody. It is possible to use.
- Didepsi peptide may be synthesized under any conditions that can achieve esterification by dehydration reaction.
- a particularly preferable reaction is a reaction performed by adding a strong base such as dimethylaminopyridine and dicyclohexylcarbodiimide to a solvent such as a dichloromethane solution.
- the obtained didepsi peptide is coupled to synthesize a tetradepsi peptide.
- any conditions may be used as long as an amide bond can be achieved.
- a method in which various condensing agents are allowed to act under neutral conditions can be adopted. It is desirable to create two types of fragments C and D for ease of subsequent synthesis.
- an octadepsipeptide is synthesized by subjecting the fragments thus obtained to an amide bond, and a dodecadepsipeptide is further synthesized.
- the method of connecting tetradepsipeptides, the position of a protecting group, etc. can be changed suitably, and it is not limited to this.
- 34 a, b having L-glutamic acid (Series a) or L-glutamic acid + aminohexanoic acid (Series b) are linked so as to be sandwiched between fragment A and fragment B.
- the amino group end of Fragment 5 can also be linked to the carboxyl group end of 34a, b by changing the position of the protecting group appropriately.
- the linear dodecadepsipeptide thus obtained is preferably cyclized to prevent the intermolecular reaction to synthesize a cereulide derivative.
- Such cereulide derivatives can be easily modified and are useful for the production of antigens for the production of antibodies. Furthermore, it can be labeled to be a tool for elucidation of the physiological function of cereulide.
- BSA bovine albumin
- KLH kabutogani hemocyanin
- Labeled cereulide which is a tool for elucidating physiological functions, can be achieved, for example, by covalently bonding a labeling substance such as biotin to the carboxyl group of a cereulide derivative.
- the next process may be applied after the neutralization process and the purification process are appropriately performed.
- Each product in each of the above steps may be isolated and purified or may be subjected to the next step as it is.
- Means for isolation and purification include washing, extraction, recrystallization, various chromatography and the like.
- Each product in each step can be carried out using these isolation and purification means alone or in combination of two or more kinds as appropriate.
- cereulide and its derivative obtained by the method of the present invention have high yield and high purity, they are highly useful as a standard of cereulide.
- a cereulide detection kit containing a preparation of cereulide.
- Such a cereulide detection kit can be provided together with a solvent for dissolving cereulide, a medium, and the like.
- it can be widely used as a potassium ion selective electrode utilizing the property of potassium ion uptake of cereulide, and application as a carcinostatic agent utilizing an apoptotic effect on cancer cells.
- more specific cancer cell selectivity can be provided.
- the cereulide derivative of the present invention can be used as it is or in the form of a pharmaceutically acceptable salt, or in the form of a formulation known to those skilled in the art mixed with them and a pharmaceutically acceptable carrier.
- salts with inorganic bases include salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like.
- salts with inorganic bases include, for example, alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; and aluminum salts, ammonium salts and the like.
- Preferred examples of the salts with organic bases include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, N'-dibenzylethylenediamine and the like.
- Preferred examples of salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- Preferred examples of the salts with organic acids include, for example, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p And salts with, for example, toluenesulfonic acid.
- Preferred examples of salts with basic amino acids include salts with arginine, lysine, ornithine and the like, and preferred examples of salts with acidic amino acids include salts with aspartic acid, glutamic acid and the like Be
- NMR spectrum JEOL JMTC-400 / 54 / SS 400 MHz (manufactured by JEOL Ltd.). Unless otherwise stated, liquid samples were measured as NaCl films, solid samples as KBr pellets, and absorption wavelengths are given in cm ⁇ 1 in the text. Furthermore, the following chemical shifts are indicated by ⁇ values. Melting point: Measured using BUCHI Melting point B-545 (all melting points are not corrected). IR: Measured using JASCO FT / IR-460 plus.
- Examples 1 to 5 represent the synthesis of cereulide of the present invention
- Examples 6 to 10 represent the synthesis of a cereulide derivative of the present invention.
- Example 1 Synthesis of Boc amino acid (1) Boc-L-Valine (1) A commercial product (manufactured by Tokyo Chemical Industry Co., Ltd.) was used without purification. ⁇ Mp; 78 ° C ⁇ [A] D -6.5 ° (c 1.0, AcOH)
- the aqueous layer was adjusted to pH 3 by adding citric acid, and extracted three times with ethyl acetate.
- the combined organic layer is washed once with saturated brine, and the organic layer is dried over anhydrous Na 2 SO 4 , concentrated under reduced pressure, and then the concentrated residue is recrystallized from ethyl acetate-hexane to give colorless crystals 2 (15.51 g, 91.3%).
- LO-valine (5) was prepared in the same manner as in the synthesis of 3 using commercially available L-valine as a raw material. That is, under the ice-cooling, sodium nitrite (10.35 g, 150 mmol) aqueous solution (50 mL) is added dropwise to a solution of L-valine (11.71 g, 100 mmol) in 1 N sulfuric acid (150 mL). Stirring was continued for 3 hours under ice cooling and then for 6 hours at room temperature.
- DO-leucine benzyl ester ⁇ benzyl (2R) -2-hydroxy-4-methylpentanoate ⁇ (4)
- DO-leucine 3, 3.36 g, 25.4 mmol
- benzyl alcohol 7.9 mL, 76.0 mmol
- para-toluenesulfonic acid monohydrate 50 mg, 0.26 mmol
- toluene 100 mL
- the reaction solution was returned to room temperature, and washed with saturated aqueous sodium hydrogen carbonate solution and then with saturated brine.
- the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure with an evaporator.
- the benzyl alcohol contained in the concentrated residue was distilled off under reduced pressure (8 mHg ⁇ ) using a glass tube oven (bulb to bulb distillation) apparatus.
- the benzyl ester (6) was synthesized in the same manner as in 4 above.
- the reaction mixture was heated to reflux for 7 hours in a reaction vessel equipped with a Dean-Stark apparatus, and subjected to the same treatment and purification to give 6 (4.57 g, 86.4%) of a pale yellow oil.
- Example 2 Synthesis of didepsi peptides (7, 8) (7) Boc-L-Val-DO-Leu-OBn (7) Under ice-cooling, a solution of DO-leucine benzyl ester (4, 5.0 g, 22.5 mmol) and commercially available Boc-L-valine (1, 5.38 g, 24.8 mmol) in dichloromethane (80 mL) was added with dimethylaminopyridine (DMAP, 0.55 g, 4.50 mmol) and then N, N'-dicyclohexylcarbodiimide (DCC, 5.86 g, 28.4 mmol) were added.
- DMAP dimethylaminopyridine
- DCC N'-dicyclohexylcarbodiimide
- the reaction solution was stirred overnight under ice cooling, and then the by-product DCurea was removed by suction filtration, and the filtrate was concentrated under reduced pressure.
- the concentrated residue was dissolved in ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate solution and then with saturated brine, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- the concentrated residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give 7 (9.30 g, 98%.) As a colorless solid.
- Boc-L-Val-DO-Leu-OH (Hydrolyzing removal of benzyl group)
- a mixture of Boc-L-Val-DO-Leu-OBn (7, 2.70 g, 6.40 mmol), methanol (30 mL), and 10% palladium carbon (135 mg) was added, and a hydrogen stream (3 The mixture was stirred at room temperature for 3 hours under atmospheric pressure. After confirming the progress of the reaction by TLC, the catalyst was filtered off and the filtrate was concentrated under reduced pressure to give 8 (2.14 g, quant) as a colorless solid. This was used for the next reaction without further purification.
- Boc-D-Ala-LO-Val-OBn (9) was performed similarly to the synthesis of 7. That is, Boc-D-alanine (2, 4.46 g, 23.6 mmol), LO-valine benzyl ester (6, 4.10 g, 19.7 mmol) and dichloromethane (50 mL) were stirred under ice-cooling and DMAP (0.72) was added thereto. g, 5.90 mmol) and then DCC (5.07 g, 24.59 mmol) were added and stirred overnight under ice-cooling.
- the by-product DCurea was filtered off with suction, the filtrate was concentrated under reduced pressure, and the concentrated residue was dissolved in ethyl acetate.
- the ethyl acetate solution was washed with saturated aqueous sodium hydrogen carbonate solution and then with saturated brine, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- the concentrated residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give 9 (7.66 g, quant) as a colorless solid.
- Example 4 Synthesis of octadepsipeptide and dodecadepsipeptide (14) Boc- (L-Val-DO-Leu-D-Ala-LO-Val) 2 -OBn (14) Under ice-cooling, N, N-diisopropylethylamine (DIPEA, 1.03 mL, 5.91 mmol) was added to a solution of fragment A • TFA salt (12, 1.75 g, 3.0 mmol) in acetonitrile (15 mL), and then fragment B (13, 13 1.49 g (3.0 mmol) of acetonitrile (5 mL) solution, O-benzotriazole-N, N, N ', N'-tetra methyl uronium hexafluorophosphate (HBTU, 1.41 g, 3.71 mmol) and 1-hydroxybenzotriazole (HOBt, 0.40) g, 3.0 mmol) was added.
- DIPEA N-d
- reaction solution was allowed to room temperature and stirred overnight, and then the solvent was evaporated under reduced pressure.
- the residue was dissolved in ethyl acetate, and the ethyl acetate layer was washed successively with 10% aqueous citric acid solution, saturated sodium hydrogencarbonate and saturated brine, and dried over anhydrous sodium sulfate. This was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give 14 (2.90 g, quant) as a colorless solid.
- Solution B was added dropwise to solution A over 1 hour using a microsyringe at room temperature, and stirring was continued at room temperature for 10 days.
- the reaction mixture was concentrated under reduced pressure to remove N, N-dimethylformamide.
- the residue was dissolved in ethyl acetate and washed successively with saturated aqueous sodium hydrogen carbonate solution, 1N hydrochloric acid and saturated brine.
- 6-aminohexanoic acid (AHA) and L-glutamic acid derivative (1) 6-aminohexanoic acid benzyl ester (AHA-OBn, 20) ⁇ p-TosOH salt
- a 6-aminohexanoic acid commercially available (AHA, 19) (6.56 g, 50.0 mmol), benzyl alcohol (15.6 mL, 150 mmol), p-TosOH monohydrate, contained in an eggplant-type flask equipped with a Dean-Stark apparatus. (11.41 g, 60.0 mmol) and toluene (150 mL) were added, and the mixture was heated under reflux for 7 hours to remove water generated by azeotropic separation.
- reaction solution was transferred to a separatory funnel, excess Troc-Cl was removed by diethyl ether extraction, citric acid was added to the aqueous layer to adjust to pH 3, and the mixture was extracted three times with ethyl acetate.
- the combined organic layer was washed once with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 22a (3.95 g, 75.7%) of a colorless oil as a residue. This was used for the next reaction without purification.
- L-OAc-valine (9) L-OAc-valine ⁇ (2R) -2-acetoxy-4-methylpentanoic acid ⁇ (30)
- L-OAc-valine was synthesized in the same manner as D-OAc-leucine. That is, acetyl chloride (15.0 mL, 211 mmol) was added to LO-valine 5 (5.00 g, 42.3 mmol) from a dropping funnel under ice-cooling. After confirming the disappearance of the starting materials by TLC, the reaction solution was concentrated under reduced pressure. A small amount of toluene was added to the residue and concentrated under reduced pressure to remove remaining acetyl chloride by coevaporation with toluene.
- L-OAc-valine tert-butyl ester (10) L-OAc-valine tert-butyl ester ⁇ tert-butyl (2S) -2-acetoxy-3-methylbutanoate ⁇ (31) L-OAc-valine tert-butyl ester was synthesized in the same manner as D-OAc-leucine tert-butyl ester. That is, a mixture of L-OAc-valine (6.73 g, 42.0 mmol), tert-butanol (40 mL) and Boc 2 O (9.17 g, 42.0 mmol) was stirred at room temperature and DMAP (1.03 g, 8.43) was added thereto. The mmol) was added slowly.
- LO-valine tert-butyl ester ⁇ tert-butyl (2S) -2-hydroxy-3-methylbutanoate ⁇ (32)
- LO-valine tert-butyl ester was synthesized similarly to LO-leucine tert-butyl ester. That is, potassium carbonate (20.83 g, 151.0 mmol) aqueous solution (60 mL) was added to a solution of L-OAc-valine tert-butyl ester (6.52 g, 30.1 mmol) in methanol (30 mL), and stirred at room temperature for 1 day .
- the concentrated residue was dissolved in ethyl acetate, and the organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and then with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- the concentrated residue was purified by silica gel column chromatography (hexane / ethyl acetate) to obtain the desired didepsipeptide 33.
- the aqueous layer was adjusted to pH 3 by addition of que BR> ⁇ and extracted three times with ethyl acetate.
- the combined organic layer is washed once with saturated brine, and the organic layer is dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then the concentrated residue is recrystallized from ethyl acetate-hexane to give colorless crystals of ZD-alanine (13.77 g, I got 91.6%).
- the concentrated residue was dissolved in ethyl acetate, and the organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and then with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- the concentrated residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give 35 (4.26 g, 78.3%) of a colorless oil.
- the reaction solution was returned to room temperature and stirred overnight, and then the reaction solution was concentrated under reduced pressure.
- the concentrated residue was dissolved in ethyl acetate, and the ethyl acetate layer was washed successively with 10% aqueous citric acid solution, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- the residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give 37 as a pale yellow oil.
- E-Celeurid and EAHA-Celeurid (cyclization reaction) (22) E-cereulide-OBn (41a) and EAHA-cereulide-OBn (41b)
- the cyclization reaction of precursor 40 was carried out in the same manner as in the synthesis of cereulide. That is, diphenyl phosphoryl azide (DPPA) (9.8 ⁇ L, 45.5 ⁇ mol) is dissolved in anhydrous N, N-dimethylformamide (12 mL), and then N, N-diisopropylethylamine (15.7 ⁇ L) in a reaction vessel purged with argon. , 90 ⁇ mol) was slowly added to prepare solution A.
- DPPA diphenyl phosphoryl azide
- precursor B (31 ⁇ mol) was dissolved in anhydrous N, N-dimethylformamide (8 mL) to prepare solution B.
- Solution B was slowly added dropwise to solution A over 1 hour using a microsyringe at room temperature, and stirring was continued at room temperature for 10 days.
- the reaction mixture was concentrated under reduced pressure to remove dichloromethane, and the residue was dissolved in ethyl acetate and washed successively with saturated aqueous sodium hydrogen carbonate solution, 1N hydrochloric acid and saturated brine.
- the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give 41 as a pale yellow solid.
- E-serourid and EAHA-seleurid (removal of benzyl group by hydrogenolysis reaction)
- a mixture of 41 (20 mg), methanol (5 mL) and 10% palladium carbon (2 mg) was placed in a hydrogenation flask, and stirred at room temperature for 3 hours under a hydrogen stream (3 atm).
- the catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain E-seleuride and EAHA-seleuride.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
に示すセレウリドまたはその誘導体を製造する方法であって、上記セレウリドまたはその誘導体の前駆体の分子内アミド結合形成による環化反応を含む、製造方法、に関する。
・NMRスペクトル:日本電子 JMTC-400/54/SS 400 MHz(日本電子社製)。特に明記しない限り、液体試料はNaClフィルム,固体試料はKBrペレットとして測定し、文中には吸収波長をcm-1で示した。)また、下記ケミカルシフトはδ値で示した。
・融点:BUCHI Melting point B-545を用いて測定した(すべての融点は補正していない)。
・IR:JASCO FT/IR-460 plusを用いて測定した。(特に明記しない限り、液体試料はNaClフィルム,固体試料はKBrペレットとして測定し、文中には吸収波長をcm-1で示した。)
・質量分析:BRUKER DALTONICS社製 MALDI-TOF-MSを用いて測定した。
・薄層クロマト (TLC):MACHEREY-NAGEL DC-Fertigplatten SIL G-25 UV254プレートを用い,次の溶媒系を用いて展開した。本文中では以下の記号で示した。
(A) n-ヘキサン:酢酸エチル=3 : 1
(B) クロロホルム:メタノール= 9 :1
(C) クロロホルム:メタノール:酢酸= 85 : 15 : 3
(D) クロロホルム:メタノール:トリエチルアミン =90 : 10 : 3
(E) トルエン:酢酸エチル= 1 :1
(F) n-ヘキサン:酢酸エチル= 1 : 1
(実施例1)
Boc アミノ酸の合成
(1) Boc-L-バリン ( 1 )
市販 (東京化成製) 品を精製することなく用いた。
・mp ; 78℃
・[a]D -6.5°(c 1.0, AcOH)
氷冷下、炭酸ナトリウム (19.1 g, 179.6 mmol) 水溶液 (150 mL) にD-アラニン ( 11, 8.0 g, 89.8 mmol) を溶解し、ここに二炭酸ジdi-tert-ブチル(Boc2O, 21. 6 g, 98.8 mmol) のTHF (20 mL) 溶液を滴下した。滴下終了後、反応液を室温に戻し一晩攪拌を続けた。反応液を分液ロートに移し、過剰のBoc2Oをジエチルエーテル抽出して除去した。水層にクエン酸を加えてpH 3に調整した後、酢酸エチルで3回抽出した。合した有機層を飽和食塩水で1回洗浄し、有機層を無水Na2SO4で乾燥、減圧濃縮した後、濃縮残渣を酢酸エチル-ヘキサンより再結晶化して無色結晶の2 (15.51 g, 91.3 %)を得た。
・TLC ; Rf = 0.48 (C)
・mp ; 83.5℃
・1H-NMR (CDCl3); 1.40-1.45 (12H, m), 4.24-4.38 (1H, m, CHCH3), 4.98-5.10 (1H, br s, NH)
・[a]D +25.1 (AcOH, c 2.02 , 26.6℃)
・IR ; 3378, 2995, 2639, 2569, 1736, 1161
(3) D-O-ロイシン {(2R)-2-ヒドロキシ-4-メチルペンタン酸} ( 3 ) 1)
氷冷下、D-ロイシン (13.11 g, 100 mmol) を1N 硫酸(150 mL)に溶解し、ここに亜硝酸ナトリウム (10.35 g, 150 mmol) の水溶液(50 mL)を滴下ロートから滴下した。反応液を氷冷下で3時間攪拌した後、室温下でさらに6時間攪拌して酢酸エチルで3回抽出した。合した有機層を飽和食塩水で1回洗浄、無水硫酸ナトリウムで乾燥、減圧濃縮した。濃縮残渣を酢酸エチル-ヘキサンから再結晶して、無色結晶のD-O-ロイシン 3 (9.60 g, 72.7 %)を得た。
・TLC ; Rf = 0.33 (C)
・mp ; 80.1℃ (lit.1) 78℃)
・1H-NMR (DMSO); 0.36 (3H, d, J = 6.34 Hz, CH(CH 3 )2), 0.38 (3H, d, J = 6.34 Hz, CH(CH 3 )2), 0.85-0.98 (2H, m, CH 2 ), 1.17-1.32 (1H, m, CH(CH3)2), 3.43 (1H, dd J1 = 8.78, J2 = 4.88, CHCH2)
・13C-NMR (DMSO); 21.55, 23.24, 23.97, 42.98, 68.22, 176.41
・[a]D + 11.7°(MeOH, c 1.03 , 22.5 ℃){lit.1) +11.8°(MeOH, c 1.03)}
・IR ; 3424, 2911, 1713
L-O-バリン ( 5 ) は、市販のL-バリンを原料として、3 の合成と同様の方法で調整した。すなわち、氷冷下、L-バリン (11.71 g, 100 mmol) の1 N 硫酸 (150 mL)溶液に、亜硝酸ナトリウム (10.35 g, 150 mmol) 水溶液 (50 mL) を滴下し、滴下終了後、氷冷下で3時間、次いで室温下で6時間攪拌を続けた。反応液を酢酸エチルで3回抽出し、合した有機層を飽和食塩水で1回洗浄して、混在する微量の硫酸を除き、無水硫酸ナトリウムで乾燥、減圧濃縮した。濃縮残渣を酢酸エチル-ヘキサンから再結晶して、5 (7.07 g, 59.9 %) を無色結晶として得た。
・TLC ; Rf = 0.37 (C)
・mp ; 64.1 ℃ (lit.2) 66 - 68 ℃)
・1 H-NMR (DMSO); 0.80 (3H, d, J = 3.17 Hz, CH(CH 3 )2), 0.87(3H, d, J = 3.17 Hz, CH(CH 3 )2), 1.85-1.95 (1H, m, CH(CH3)2), 3.72 (1H, d, J = 4.63Hz, CHCH(CH3)2), 5.02 (1H, br, COOH)
・13C-NMR (DMSO); 16.89, 19.05, 31.55, 74.64, 175.51
・[a]D +16.8°(CHCl3, c 1.01 , 23.5 ℃) { lit.2); + 20°(CHCl3, c 4)}
・IR ; 3433, 2970, 2186, 1714
D-O-ロイシン ( 3, 3.36 g, 25.4 mmol)、ベンジルアルコール (7.9 mL, 76.0 mmol)、パラトルエンスルホン酸・1水和物 (50 mg, 0.26 mmol)、およびトルエン(100 mL)の混合物をDean-Stark装置を取り付けたナス型フラスコ中で7時間加熱還流し、共沸分離により発生した水を除いた。TLCで原料の消失を確認した後、反応液を室温に戻し、飽和炭酸水素ナトリウム水溶液、次いで飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥、エバポレ-タで減圧濃縮した。濃縮残渣中に含まれるベンジルアルコールをガラスチューブオーブン (bulb to bulb蒸留) 装置を用いて、減圧下 (8 mHg <) で留去した。この残渣をシリカゲルカラムクロマトグラフィー (ヘキサン:酢酸エチル=90:10) により精製して、淡黄色油状物4 (4.95 g, 80.8 %) を得た。
・TLC ; Rf = 0.38 (A)
・1H-NMR (CDCl3); 0.91(3H, d, J = 4.39 Hz, CH(CH 3 )2), 0.94(3H, d, J = 4.39 Hz,CH(CH 3 )2), 1.56-1.62 (2H, m, d, CH 2 ), 2.60-2.65 (1H, m, OH),4.18-4.26 (1H, m, CHCH2), 5.19 (2H, ABq, CH 2 Ph), 7.30-7.40 (5H, m, ArH)
・13C-NMR (CDCl3); 21.52, 23.21, 24.39, 67.25, 69.15, 128.30, 128.30, 128.52, 128.64, 135.21, 175.71)
・[a]D + 15.4°(CHCl3, c 1.02 , 26.8 ℃)
・IR ; 3475, 2956, 2872, 1736, 1607, 1497, 1140
ベンジルエステル ( 6 ) は上記 4 と同様の方法で合成した。
L-O-バリン ( 5,3.0 g, 25.4 mmol )、ベンジルアルコール (7.9 mL, 76.0 mmol)、 p-トルエンスルホン酸・1水和物 (50 mg, 0.26 mmol)、およびトルエン (100 mL)、の混合物をDean-Starkの装置を取り付けた反応容器中で7時間加熱還流し,同様の処理と精製を行って,淡黄色油状物の6 (4.57 g, 86.4 %) を得た。
・TLC ; Rf = 0.44 (A)
・1H-NMR (CDCl3); 0.83( 3H, d, J = 6.09 Hz, CH(CH 3 )2 ), 1.01( 3H, d, J = 6.09 Hz, CH(CH 3 )2 ), 2.02-2.14(1H, m, CH(CH3)2), 2.69 (1H, d, J = 6.09, OH), 4.06-4.11(1H, m, CHCH), 5.22 (2H, ABq, CH 2 Ph), 7.31-7.60 (5H, m, ArH)
・13C-NMR (CDCl3); 15.82, 18.77, 32.14, 67.29, 74.98, 128.41, 128.56, 128.64, 135.16, 174.82
・[a]D -9.60°(CHCl3, c 2.19 , 26.0℃)
・IR ; 3505, 3065, 3034, 2965, 2934, 2876, 1733, 1497, 1460, 1137
ジデプシペプチド ( 7, 8 )の合成
(7)Boc-L-Val-D-O-Leu-OBn ( 7 )
氷冷下、D-O-ロイシン ベンジル エステル ( 4, 5.0 g, 22.5 mmol) および市販のBoc-L-バリン ( 1, 5.38 g, 24.8 mmol) のジクロロメタン (80 mL) 溶液に、ジメチルアミノピリジン (DMAP, 0.55 g, 4.50 mmol)、次いでN,N'-ジシクロヘキシルカルボジイミド (DCC, 5.86 g, 28.4 mmol) を加えた。この反応液を氷冷下で一晩攪拌した後、副成したDCureaを吸引濾過して除き、濾液を減圧濃縮した。濃縮残渣を酢酸エチルに溶かして、飽和炭酸水素ナトリウム水溶液、次いで飽和食塩水で洗浄し、有機層を無水硫酸ナトリウムで乾燥、減圧濃縮した。この濃縮残渣をシリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル)より精製して、無色固体の 7 (9.30 g, 98 %.) を得た。
・TLC ; Rf = 0.56 (A)
・1H-NMR (CDCl3); 0.78-0.92 (12H, m, CH(CH 3 )2), 1,37 (9H, s, tert-Bu), 1.50-1.82(3H, m), 2.02-2.20 (1H, m, CH(CH3)2), 4.18-4.32 (1H, m, CHCH2CH(CH3)2), 4.91 (1H, d, J = 8.78 Hz, NH), 5.04 (1H, dd, J1 = 10.0 Hz, J2 = 3.66 Hz), 5.10 (2H, ABq, CH 2 Ph), 7.28-7.36 (5H, m, ArH)
・13C-NMR (CDCl3); 17.31, 19.04, 21.27, 23.04, 24.49, 28.30, 31.23, 39.62, 58.62, 67.04, 71.59, 79.72, 128.22, 128.41, 128.59, 135.22, 155.49, 170.12, 171.78
・[a]D + 15.58°(CHCl3, c 0.40 , 16.6 ℃)
・IR ; 3384, 2964, 2875, 1746, 1717, 1501, 1462, 1177
水素添加用フラスコに、Boc-L-Val-D-O-Leu-OBn (7, 2.70 g, 6.40 mmol)、メタノール (30 mL)、および10% パラジウム炭素 (135 mg) の混合物入れ、水素気流(3気圧)下、室温で3時間攪拌した。TLCで反応の進行を確認した後、触媒を濾去し、濾液を減圧濃縮して無色固体の8 (2.14 g, quant) を得た。これは、これ以上精製することなく次の反応に用いた。
・TLC ; Rf = 0.55 (C)
・mp ; 95.8℃
・1H-NMR (CDCl3); 0.86-1.06 (12H, m, CH(CH 3 )2), 1.44 (9H, s, tert-Bu), 1.72-1.80(2H, m, CH 2 CH(CH3)2), 1.80-1.86 (1H, m, CHCH(CH3)2), 2.14-2.28 (1H, m, CH2CH(CH3)2), 4.22-4.33 (1H, m, CHCH2), 5.00-5.06 (1H, m, NH), 5.06-5.14 (1H, m, CHCH(CH3)2)
・13C-NMR (CDCl3); 17.49, 19.06, 21.17, 23.06, 24.54, 28.28, 30.93, 39.62, 52.49, 58.86, 69.99, 71.19, 80.19, 113.79, 121.42, 155.84, 174.30
・IR ; 3516, 3396, 3093, 2961, 2606, 1726, 1520, 1463, 1409, 1178
ジデプシペプチド( 9 ) は、7 の合成と同様に行った。すなわち、Boc-D-アラニン ( 2, 4.46 g, 23.6 mmol)、L-O-バリン ベンジル エステル ( 6, 4.10 g, 19.7 mmol) およびジクロロメタン (50 mL) を氷冷下に撹拌し、ここにDMAP (0.72 g, 5.90 mmol) 、次いで DCC (5.07 g, 24.59 mmol) を加え、氷冷下で一晩攪拌した。副成したDCureaを吸引濾去、濾液を減圧濃縮して、濃縮残渣を酢酸エチルに溶かした。この酢酸エチル溶液を飽和炭酸水素ナトリウム水溶液、次いで飽和食塩水で洗浄し、有機層を無水硫酸ナトリウムで乾燥、減圧濃縮した。濃縮残渣をシリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル)より精製して、無色固体の9 (7.66 g, quant) を得た。
・TLC ; Rf = 0.56 (A)
・mp ; 63.4℃
・1H-NMR (CDCl3); 0.94 (3H, d, J = 6.83 Hz, CH(CH 3 )2), 0.98 (3H, d, J = 6.83 Hz,CH(CH 3 )2), 1.41 (3H, d, J = 7.07 Hz, CHCH 3 ), 1.45 (9H, s, tert-Bu), 2.22-2.34 (1H, m, CH(CH3)2), 4.43-4.50 (1H, m, CHCH3), 4.93 (1H, d, J = 4.39, CHCHCH3), 5.03 (1H, br, NH), 5.18 (2H, ABq, CH 2 Ph), 7.28-7.40 (5H, m, ArH)
・13C-NMR (CDCl3); 17.01, 18.59, 18.70, 28.31, 30.12, 49.33, 66
.97, 79.76, 128.32, 128.43, 135.22, 154.91, 169.06, 172.74
・IR ; 3396, 2976, 1741, 1688, 1509, 1459, 1161
・[a]D - 10.70°(CHCl3, c 1.02, 27.0℃)
氷冷下、Boc-L-Val-D-O-Leu-OBn ( 9 ) (2.43 g, 6.40 mmol) のジクロロメタン (7.5 mL) 溶液に、トリフルオロ酢酸 (TFA, 7.5 mL) を加えた。この反応液を氷冷下で30分間、次いで室温下で30分間攪拌した。TLCでBoc基が除去されたことを確認した後、減圧濃縮して淡黄色油状物の10 (2.41 g, quant) をTFA塩として得た。これは、これ以上精製することなく次の反応に用いた。
・TLC ; Rf = 0.51 (B)
・1H-NMR (CDCl3); 0.82 (3H, d, J = 6.83 Hz, CH(CH 3 )2), 0.87 (3H, d, J = 6.83 Hz, CH(CH 3 )2), 1.54 (3H, d, J = 7.32 Hz, CHCH 3 ), 2.12 (1H, m, CH(CH3)2), 4.12 (1H, q, J = 7.32 Hz, CHCH3), 4.91 (1H, d, J = 4.15, CHCH(CH3)2), 5.06(2H, ABq, CH 2 Ph), 7.20-7.30(5H, m, ArH)
・13C-NMR (CDCl3); 15.54, 16.77, 18.40, 30.05, 49.01, 67.39, 78.35, 128.45, 128.57, 128.60, 134.96, 168.69, 169.70
・IR ; 3420, 3035, 2970, 1742, 1674, 1527, 1461, 1141
(11)テトラデプシペプチド、フラグメントAおよびフラグメントBの合成(11)Boc-L-Val-D-O-Leu-D-Ala-L-O-Val-OBn ( 11 ) 氷冷下,ジデプシペプチドH2N-D-Ala-L-O-Val-OBn・TFA塩( 10, 2.41 g, 6.40 mmol) のアセトニトリル (10 mL) 溶液に、N,N-diisopropylethylamine (DIPEA, 1.12 mL, 6.43 mmol) を加えて中和した後、Boc-L-Val-D-O-Leu-OH ( 8, 2.14 g,6.40 mmol) のアセトニトリル溶液 (5 mL) を加え、次いで1-ethyl-3-(3-diメチルaminopropyl)carbodiimide (EDC) 塩酸塩 (1.35 g, 7.04 mmol) を加えた。氷冷バスを取り除いて、室温下で一晩攪拌した後、溶媒を減圧留去した。この残渣を酢酸エチルに溶解して、有機層を10%クエン酸水溶液、飽和炭酸水素ナトリウム水溶液、および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥、減圧濃縮した。この残渣をシリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル)により精製して、無色油状物の11 (3.56 g, 94 %)を得た。
・TLC ; Rf = 0.33 (A)
・1H-NMR (CDCl3); 0.84-1.04 (18H, m, CH(CH 3 )2), 1.41 (9H, s, tert-Bu), 1.64-1.84 (3H, m), 2.06-2.15 (1H, m, , CHCH(CH3)2), 2.18-2.30 (1H, m, CH2 CH(CH3)2), 4.06-4.17 (1H, m, CHCH3), 4.52- 4.63 (1H, m, CHCH2CH(CH3)2), 4.86-4.94 (1H, m, CHCH(CH3)2), 5.00-5.05 (1H, m, NH), 5.08-5.27 (2H, m, CH 2 Ph), 5.26-5.34 (1H, m, CHCH(CH3)2), 7.09-7.14 (1H, br, NH), 7.28-7.38 (5H, m, ArH)
・13C-NMR (CDCl3); 16.97, 17.24, 18.06, 18.68, 19.17, 21.38, 23.20, 24.33, 28.25, 30.10, 30.44, 34.54, 40.51, 48.53, 59.53, 63.52, 66.96, 72.66, 80.24, 100.55, 128.36, 128.40, 128.55, 135.27, 155.89, 169.11, 169.79, 170.43, 171.77
・[a]D + 16.03(CHCl3, c 0.62 , 23.5 ℃)
・IR ; 3344, 2968, 2878, 1756, 1681, 1530, 1462, 1056
保護された繰り返し構造単位 ( 11, 2.43 g, 6.40 mmol)をジクロロメタン (7.5 mL) に溶解し、氷冷下にTFA (7.5 mL) を加え30分間攪拌した後、室温で30分間攪拌した。TLCで反応の終了を確認した後、反応液を減圧濃縮した。この残渣に少量のトルエンを加え、減圧濃縮して残存するTFAをトルエンとのコエバポレーションにより除いた。この操作を3回繰り返し、淡黄色油状物の12 (2.42 g, quant) を得た。これは、これ以上の精製すること無く次の反応に用いた。
・TLC ; Rf = 0.59 (C)
・1H-NMR (CDCl3); 0.88-1.16 (18H, m, CH(CH 3 )2), 1.52 (3H, d, J = 7.32 Hz, CHCH 3 ), 1.70-1.85 (6H, m), 2.18-2.30 (1H, m, CH2 CH(CH3)2), 2.38- 2.51 (1H, m, CH2 CH(CH3)2), 4.09-4.15 (1H, m, CHCH3), 4.58- 4.67 (1H, m, CHCH2CH(CH3)2), 4.86-4.94 (1H, m, CHCH(CH3)2), 5.00-5.05(1H, m, NH), 5.08-5.27(2H, m, CH 2 Ph), 5.26-5.34 (1H,m, CHCH(CH3)2), 7.09-7.14 (1H, br, NH), 7.28-7.38(5H, m, ArH)
・13C-NMR (CDCl3); 17.04, 17.08, 18.22, 18.35, 18.61, 21.52, 22.98, 24.30, 29.94, 30.14, 40.74, 48.47, 58.90, 67.02, 74.32, 128.32, 128.40, 128.54, 135.16, 168.33, 169.25, 169.40, 172.25
・IR ; 3221, 2964, 1748, 1675, 1531, 1461, 1156
保護された繰り返し構造単位( 11, 2.70 g, 6.40 mmol) のメタノール溶液 (20 mL) および10% パラジウム炭素 (135 mg) の混合物を中圧水添用フラスコに入れ、水素気流 (3気圧) 下、室温で4時間攪拌した。TLCで反応の進行を確認した後、溶媒を減圧留去して無色油状物の 13 (2.12 g, quant) を得た。これは、精製すること無く次の反応に用いた。
・TLC ; Rf = 0.18 (C)
・1H-NMR (CDCl3); 0.87-1.04 (18H, m, CH(CH 3 )2), 1.42-1.50(12H, m), 1.60-1.81 (3H, m), 2.09-2.18 (1H, m, , CHCH(CH3)2), 2.25-2.35 (1H, m, CH2 CH(CH3)2), 4.13-4.23 (1H, m, CHCH3), 4.52-4.62 (1H, m, CHCH2CH(CH3)2), 5.04-5.12(2H, m), 5.32-5.38 (1H, m, CHCH(CH3)2), 7.34-7.39 (1H, d, J = 7.56 Hz, NH)
・13C-NMR (CDCl3); 16.78, 16.83, 17.87, 18.78, 19.12, 21.20, 23.20, 24.30, 28.21, 29.93, 30.39, 40.60, 48.28, 59.40, 72.80, 77.21, 80.64, 156.33, 170.45, 171.82, 171.94
・IR ; 3341, 2968, 2882, 1748, 1688, 1531, 1464, 1371, 1249, 1162, 1057, 1016, 757
オクタデプシペプチド、およびドデカデプシペプチドの合成
(14)Boc-(L-Val-D-O-Leu-D-Ala-L-O-Val)2-OBn ( 14 )
氷冷下、フラグメントA・TFA 塩 ( 12, 1.75 g, 3.0 mmol) のアセトニトリル (15 mL) 溶液に、N,N-diisopropylethylamine (DIPEA, 1.03 mL, 5.91 mmol) を加え、次いでフラグメントB ( 13, 1.49 g,3.0 mmol) のアセトニトリル( 5 mL) 溶液、O-benzotriazole-N,N,N’,N’-tetraメチルuronium hexafluorophosphate (HBTU, 1.41 g, 3.71 mmol) および 1-ヒドロキシbenzotriazole (HOBt, 0.40 g, 3.0 mmol) を加えた。反応液を室温に戻して一晩攪拌した後、溶媒を減圧留去した。この残渣を酢酸エチルに溶解し、酢酸エチル層を10%クエン酸水溶液、飽和炭酸水水素ナトリウムおよび飽和食塩水で、順次、洗浄して無水硫酸ナトリウムで乾燥した。これを減圧濃縮して、残渣をシリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル) によって精製し、無色固体の14 (2.90 g, quant) を得た。
・TLC ; Rf = 0.14 (A)
・mp ; 57~59 ℃
・1H-NMR (CDCl3); 0.84-1.07 (36H, m), 1.43 (9H, s), 1.47 (3H, d, J = 7.56 Hz), 1.49 (3H, d, J = 7.32 Hz), 1.65-1.84 (6H, m), 1.97-2.05 (1H, m), 2.29-2.37 (1H, m), 2.37-2.38 (1H, m), 3.88 (3H, t, J = 6.59 Hz), 4.08-4.13 (1H, m), 4.38 (1H, t, J= 7.81 Hz), 4.58-4.63 (1H, m), 4.85 (1H, d, J= 4.39 Hz), 5.03 (1H, d, J = 5.85 Hz), 5.09-5.20 (4H, m), 5.37 (1H, dd, J = 3.17, 10.0 Hz), 5.04-5.12(2H, m), 7.30-7.37 (5H, m), 7.68 (1H, d, J = 7.32 Hz), 7.68 (1H, d, J = 7.32 Hz), 7.68 (1H, d, J = 6.10 Hz)
・13C-NMR (CDCl3) ; 14.17, 16.43, 16.97, 17.51, 18.64, 18.93, 18.98, 19.31, 19.45, 20.80, 21.05, 21.10, 23.14, 23.36, 24.22, 24.34, 28.22, 29.82, 30.04, 30.09, 40.35, 40.99, 48.25, 49.52, 58.74, 60.34, 60.39, 66.73, 72.41, 72.73, 77.21, 78.68, 80.93, 128.24, 128.28, 128.49, 135.36, 156.45, 169.12, 170.00, 170.42, 170.67, 171.65, 171.91, 172.44
・IR ; 3319, 2966,2876, 1751, 1656, 1537, 1463, 1185
・[a]D+ 12.7°(CHCl3, c 1.01 , 26.5 ℃)
保護されたオクタデプシペプチド 14 (1.00 g, 1.02 mmol)、メタノール (30 mL) および10% パラジウム炭素(50 mg)の混合物を水添用フラスコ中に入れ、水素気流 (3気圧)下、室温で4時間攪拌した。TLCで反応の進行を確認した後、パラジウム触媒を濾去し減圧濃縮して無色油状物の15 (0.88 g, 97 %)を得た。これは、精製すること無く次の反応に用いた。
・TLC ; Rf = 0.67 (C)
・mp ; 85~87 ℃
・1H-NMR (CDCl3); 0.80-1.06 (36H, m), 1.43 (9H, s), 1.47 (3H, d, J = 7.07 Hz), 1.52 (3H, d, J= 7.07 Hz), 1.62-1.84 (6H, m), 1.96-2.08 (1H, m), 2.19-2.38 (3H, m), 3.93 (1H, t, J = 6.83 Hz), 4.12-4.22 (1H, m), 4.22-4.31 (1H, m), 4.44-4.61 (1H, m), 4.94-5.02 (2H, m), 5.09 (1H, d, J = 6.09 Hz), 7.65 (1H, d, J = 6.83 Hz), 7.74 (1H, d, J = 5.85 Hz), 7.83 (1H, d, J = 7.32 Hz)
・IR ; 3060, 2966, 2876, 1751, 1658, 1535, 1465, 1389, 1370, 1301, 1241, 1155, 1058, 1010, 931, 877, 838, 782, 628
氷冷下、フラグメントB ( 13 )・TFA塩・(479 mg, 0.81 mmol) のアセトニトリル( 5 mL) 溶液を入れ、DIPEA (0.14 mL, 0.81 mmol) を加えて中和した後、 オクタデプシペプチド 15 (720 mg, 0.81 mmol) のアセトニトリル (5 mL) 溶液を加えた。次いで、O-(7-アザベンゾトリアゾール-1-yl)-N,N,N',N'-tetraメチルウロニウムヘキサフルオロフォスフェート ( HATU, 334 mg, 0.88 mmol)を加えた。反応液を室温に戻して一晩攪拌した後、減圧濃縮して、残渣を酢酸エチルに溶解し、酢酸エチル層を10%クエン酸水溶液、飽和炭酸水素水ナトリウム水溶液および飽和食塩水で、順次、洗浄した。この有機層を無水硫酸ナトリウムで乾燥、次いで減圧濃縮して、残渣をシリカゲルカラムクロマトグラフィー
(ヘキサン/酢酸エチル=7:3)により精製し、無色固体の16 (905 mg, 82 %) を得た。
・TLC ; Rf = 0.33(F)
・mp ; 71~73 ℃
・1H-NMR (CDCl3); スペクトラムを図2に示す。
・13C-NMR (CDCl3) ; 14.06, 16.27, 16.34, 16.41, 16.53, 17.09, 17.15, 17.68, 18.57, 18.94, 18.98, 19.05, 19.17, 19.20, 19.31, 19.40, 20.69, 20.81, 21.12, 23.03, 23.15, 23.31, 24.20, 24.35, 28.23, 29.74, 30.02, 30.11, 30.15, 30.38, 40.53, 40.90, 41.18, 48.17, 49.36, 49.62, 58.27, 58.73, 60.40, 66.62, 72.41, 72.74, 77.21,
78.88, 79.09, 80.91, 128.20, 128.45, 135.41, 156.56, 169.22, 169.71, 169.96, 170.36, 170.51, 170.56, 170.81, 171.90, 172.45
・[a]D + 6.12 ° (CHCl3, c 1.02 , 25.9 ℃)
・IR; 3320, 2965, 2876, 1751, 1655, 1538, 1466, 1370, 1336, 1242, 1184, 1153, 1058, 1006, 933, 876, 747, 697
保護されたドデカデプシペプチド 16 (133 mg,97.7 μmol)、メタノール( 5 mL) 10% パラジウム炭素(7 mg)の混合物を水添添加用の反応容器に入れ、水素気流 (3 気圧) 下、室温で3時間攪拌した。TLCで反応の進行を確認した後、溶媒を減圧留去し、無色固体の17 (120.2 mg, 97 %) を得た。これは、精製すること無く次の反応に用いた。
・TLC ; Rf = 0.33(B)
・mp ; 97~99 ℃
・1H-NMR (CDCl3); スペクトラムを図3に示す。
・13C-NMR (CDCl3) ; 16.33, 16.39, 16.48, 16.60, 16.78, 16.88, 18.78, 18.84, 18.94, 19.03, 19.18, 19.24, 19.26, 19.31, 20.92, 21.09, 23.18, 23.34, 24.32, 24.39, 28.28, 29.51, 29.86, 29.92, 30.21, 30.22, 40.52, 40.82, 48.26, 49.35, 49.54, 58.82, 59.06, 60.30, 72.77, 72.82, 73.02, 77.23, 77.58, 78.99, 79.04, 80.89, 156.55, 170.46, 170.65, 170.84, 170.97, 171.21, 171.55, 172.11, 172.36, 172.53
・IR ; 3319, 3068, 2965, 2938, 2876, 1751, 1658, 1536, 1467, 1389, 1370, 1335, 1308, 1249, 1185, 1154, 1128, 1109, 1058, 1008, 933, 877, 755
・TLC ; Rf = 0.45 (B)
・mp ; 118~121 ℃
・1H-NMR (CDCl3); スペクトラムを図4に示す。
・IR; 3310, 3060, 2965, 2882, 2360, 1749, 1659, 1542, 1466, 1389, 1208, 1154, 1059, 1007
セレウリドの合成(環化反応)
(19)セレウリド
アルゴン置換した反応容器に、ジフェニルホスホリルアジド(DPPA) (9.8 μL, 45.5 μmol)を、無水N,N- ジメチルホルムアミド( 12 mL )に溶解し、次いで、N,N-ジイソプロピルエチルアミン (15.7 μL, 90 μmol) を加えて、A液を調製した。別途、前駆体 18 (40 mg, 31.5 μmol) を,無水N,N- ジメチルホルムアミド(8 mL) に溶解したB液を調整した。室温下、マイクロシリンジを用いて、A液にB液を1時間以上かけて滴下し、10日間、室温下で攪拌を続けた。反応液を減圧濃縮してN,N- ジメチルホルムアミドを留去し、残渣を酢酸エチルに溶解して、飽和炭酸水素ナトリウム水溶液、1N 塩酸および飽和食塩水で、順次洗浄した。この有機層を無水硫酸ナトリウムで乾燥、減圧濃縮して、残渣をシリカゲルカラムクロマトグラフィー (ヘキサン/酢酸エチル=7:3)より精製し、淡黄色固体のセレウリド (5.2 mg, 14%) を得た。これを熱 n-ヘキサンより再結晶して、純粋なセレウリドを無色結晶として得た。
・TLC ; Rf = 0.23 (F)
・mp ;200℃ (lit.5) 196-199 ℃)
・1H-NMR (CDCl3) ; 0.85-1.02 (m, 45 H), 1.06 (d, J = 6.59 Hz, 9H), 1.46 (d, J = 7.07 Hz, 9H), 1.59-1.85 (m, 9H), 2.24-2.39 (m, 6H), 4.10 (dd, J = 9.27, 7.81 Hz, 3H), 4.37-4.42 (m, 3H), 5.01 (d, J = 3.17 Hz, 3H), 5.32 (dd, J = 7.81, 5.12 Hz, 3H), 7.81 (d, J = 6.83 Hz, 6H)
スペクトラムを図5に示す。
・13C-NMR (CDCl3) ; 15.75, 16.85, 18.55, 19.28, 21.20, 23.34, 24.37, 28.62, 30.48, 40.54, 48.78, 9.45, 72.69, 78.62, 170.49, 171.07, 171.49, 171.87
・[a]D +10.5℃(CHCl3, c 0.78, 25℃),{lit.5) +3.37°(CHCl3, c 1.03)}
・IR; 3303, 2963, 2875, 1744, 1656, 1539, 1467, 1246, 1190, 1149, 1057, 1008
・MALDI/TOFMS; 1175.576 [M + Na]+, 1191.561 [M + K]+
6-アミノヘキサン酸 (AHA) および L-グルタミン酸誘導体
(1)6-アミノヘキサン酸 ベンジルエステル (AHA-OBn, 20 )・p-TosOH塩
Dean-Stark装置を取り付けたナス型フラスコに、市販の6-アミノヘキサン酸 (AHA, 19) (6.56 g, 50.0 mmol)、ベンジルアルコール (15.6 mL, 150 mmol)、 p-TosOH・1水和物 (11.41 g, 60.0 mmol)、およびトルエン (150 mL) を入れ、7時間、加熱還流して発生する水を共沸分離により除いた。TLCで原料の消失を確認した後、反応液を室温に戻してヘキサンを加え、析出した結晶を吸引濾取した。結晶を冷酢酸エチルでよく洗浄して、無色固体の20 ( 18.71 g, 95.1 % ) を得た。
・TLC ; Rf = 0.35 (D)
・mp ; 107.9 ℃
・1H-NMR (CD3OD) ; 1.29-1.44 (2H, m), 1.54-1.69 (4H, m), 2.33-3.34 (5H, m), 2.80-2.90 (2H, m), 3.26-3.34 (2H, m), 5.11 (2H, s), 7.22 (2H, d, J= 7.81), 7.28-7.37 (5H, m), 7.66-7.72 (2H, m)
・13C-NMR (CD3OD) ; 21.31, 25.37, 26.79, 28.17, 34.60, 40.50, 67.21, 126.92, 129.92, 129.23, 129.26, 129.55, 129.85, 137.65, 141.75, 143.45, 174.86
・IR ; 3050, 2945, 2634, 2042, 1730, 1622, 1476, 1248
氷冷下,炭酸水素ナトリウム (3.19 g, 38.0 mmol) 水溶液 (60 mL) に市販 (渡辺化学工業製) のL-グルタミン酸 g-ベンジルエステル 21 (3.00 g, 12.6 mmol) を溶解し,ここに2,2,2-trichloroethyl chloroformate (Troc-Cl) (2.20 mL, 16.0 mmol) のジエチルエーテル (10 mL) 溶液を滴下した。滴下終了後,反応液を室温に戻して,一晩攪拌を続けた。反応液を分液ロートに移し,過剰のTroc-Clをジエチルエーテル抽出により除き,水層にクエン酸を加えてpH3に調整した後,酢酸エチルで3回抽出した。合した有機層を飽和食塩水で1回洗浄し,無水硫酸ナトリウムで乾燥,減圧濃縮して残渣に無色油状物の22a (3.95 g, 75.7 %) を得た。これは,精製すること無く次の反応に用いた。
・TLC ; Rf = 0.56 (A)
・1H-NMR (CDCl3) ; 2.07-2.19 (1H, m), 2.18-2.29 (1H, m), 2.31-2.43 (1H, m), 2.46-2.65 (2H, m), 4.54-4.63 (1H, m), 4.66-4.78 (2H, m,), 5.14 (2H, s), 5.72 (1H, d,
J = 8.05Hz), 7.30-7.40 (5H, m, ArH)
・IR ; 3328, 3035, 2955, 2629, 1732, 1452, 1391, 1214
氷冷下,市販 (渡辺化学工業製) のL-グルタミン酸 tert-ブチルエステル 23 ( 1.00 g, 4.92 mmol ) を炭酸水素ナトリウム (827 mg, 9.84 mmol) 水溶液 (10 mL) に溶解し,ここにTroc-Cl (0.80 mL, 5.97 mmol) のジエチルエーテル (3 mL ) 溶液を滴下した。22aと同様の反応処理を行って、無色油状物の24 (1.61 g, 86.4 %) を得た。これは,精製すること無く次の反応に用いた。
・TLC ; Rf = 0.56 (A)
・1H-NMR (CDCl3) ; 1.49 (9H, s), 1.92-2.08 (1H, m), 2.18-2.30 (1H, m), 2.36-2.56
(2H, m), 4.27-4.36 (1H, m), 4.64-4.81 (2H, m), 4.73 (1H, d, J = 7.81 Hz)
・13C-NMR (CDCl3) ; 27.51, 27.93, 29.79, 53.79, 74.61, 83.03, 95.29, 154.21, 170.52, 178.12
・IR ; 3336, 2980, 1720, 1528, 1452, 1395, 1370, 1230
氷冷下,20 p-Tos-OH塩 (1.83 g, 4.65 mmol) のアセトニトリル (7 mL) 溶液に,DIPEA (1.84 mL, 10.6 mmol) を加えて中和した後,ここに 24 (1.60 g, 4.23 mmol) のアセトニトリル溶液 (3 mL) を加え,次いでEDC 塩酸塩 (972 mg, 5.04 mmol) およびHOBt (571 mg, 4.23 mmol ) を加えた。氷冷バスを取り去って,反応液を室温下で一晩攪拌した後,溶媒を減圧留去した。この残渣を酢酸エチルに溶解して,有機層を10% クエン酸水溶液,飽和炭酸水素ナトリウム水溶液,および飽和食塩水で洗浄し,無水硫酸ナトリウムで乾燥,減圧濃縮した。この残渣をシリカゲルカラムクロマトグラフィー(クロロホルム) より精製して,無色油状物の 25 (1.82 g, 74 %) を得た。
・TLC ; Rf = 0.69 (B)
・1H-NMR (CDCl3) ; 1H-NMR (CDCl3) ; 1.30-1.40 (2H, m), 1.43-1.56 (11H, m), 1.62-1.70 (2H, m), 1.91-2.03 (1H, m), 2.17-2.30 (3H, m), 4. 37 (2H, t, J = 7.32 Hz), 3.17-3.31 (2H, m), 4.17-4.27 (1H, m), 4.63-4.81 (2H, m), 5.11 (2H, s), 5.90 (1H,
d, J = 7.56 Hz), 7.31-7.39 (5H, m)
・13C-NMR (CDCl3) ; 24.36, 26.25, 27.91, 28.71, 29.06, 32.42, 34.00, 39.31, 54.15, 66.13, 74.54, 82.71, 95.33, 128.16, 128.18, 128.51, 135.91, 154.56, 170.61,171.68, 173.39
・IR ; 3322, 3034, 2938, 2867, 1734, 1651, 1537, 1454, 1369, 1229
氷冷下、25 (913 mg, 1.57 mmol) のジクロロメタン (5.0 mL) 溶液に、トリフルオロ酢酸 (5.0 mL) を加えて30分間撹拌し、次いで室温下で2.5時間攪拌した。TLCで反応終了を確認した後、減圧濃縮して淡黄色油状物の22b・TFA 塩 (825 mg, quant.) を得た。これは、精製すること無く次の反応に用いた。
・TLC ; Rf = 0.50 (C)
・1H-NMR (CDCl3) ; 1.30-1.39 (2H, m, CH2), 1.46-1.57 (2H, m, CH2), 1.59-1.70 (2H, m, CH 2 ), 2.06-2.14 (1H, m, CHCH 2 CH2CO), 2.18-2.29 (1H, m, CHCH 2 CH2CO), 2.34-2.46 (4H, m, CH2), 3.20-3.30 (2H, m, CH2), 4.32-4.39 (1H, m, CHCH2CH2CO), 4.64-4.90 (2H, m, CH 2 CCl3), 5.12 (2H, s, CH 2 Ph), 6.28 (1H, d, J = 7.32, NH), 6.36-6.41 (1H, m, NH), 7.30-7.40 (5H, m, ArH)
・13C-NMR (CDCl3) ; 24.24, 26.15, 28.68, 28.99, 32.43, 33.98, 39.71, 54.43, 66.35, 74.65, 95.32, 128.22, 128.30, 128.60, 135.88, 154.52, 172.92, 173.73, 173.76
・[a]D+ 8.57°(CHCl3, c 0.46, 16.4 ℃)
・IR ; 3341, 2942, 2602, 1733, 1626, 1541, 1450, 1230, 736
(6)D-OAc-ロイシン {(2R)-2-アセトキシ-4-メチルペンタン酸} ( 27 )氷冷下、D-O-ロイシン 26 ( 3, 3.36 g, 25.4 mmol ) に、塩化アセチル(13.4 mL,154 mmol)を,滴下ロートを用いて加えた。 TLCで原料の消失を確認した後、反応液を減圧濃縮した。この濃縮残渣中の塩化アセチルを完全に取り除くために、少量のトルエンとのコエバポレーション操作を3回繰り返して行い、無色油状物の27 (6.52 g,quant.) を得た。これは精製すること無くの反応に用いた。
・TLC ;Rf= 0.61 (C)
・1H-NMR (CDCl3); 0.94 (3H, d, J= 6.34, CH(CH 3 )2), 0.97 (3H, d, J= 6.34, CH(CH 3 )2) 1.64-1.72 (1H, m, CH(CH3)2), 1.75-1.86 (2H, m, CH 2 CH(CH3)2), 2.15(3H, s, COCH 3 ), 5.01-5.07 (1H, m, CH CH2)
・13C-NMR (CDCl3); 20.53, 21.41, 22.91, 24.57, 39.50, 70.55, 170.79, 176.70
室温下で27 (6.52 g, 37.4 mmol)、tert-ブタノール (40 mL), およびBoc2O (8.26 g, 37.8 mmol)の混合物に、DMAP ( 0.92 g, 7.53 mmol ) をゆっくりと加えた。室温で5時間攪拌した後、反応液を減圧濃縮し、濃縮残渣をシリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル)より精製して無色油状物の28 (6.56 g, 70.1 %) を得た。
・TLC ;Rf = 0.54 (A)
・1H-NMR (CDCl3); 0.92 (3H, d, J= 6.83, CH(CH 3 )2), 0.96 (3H, d, J= 6.58 Hz, CH(CH 3 )2), 1.46 (9H, s, tert-Bu), 1.55-1.64 (1H, m, CH(CH3)2), 1.69-1.82 (2H, m, CH 2 CH(CH3)2), 2.12(3H, s, COCH 3 ), 4.85-4.92 (1H, m, CH CH2)
・13C-NMR (CDCl3); 20.70, 21.56, 22.99, 24.62, 27.91, 39.71, 71.52, 81.89, 169.94, 170.64
・IR ; 2963, 2875, 1746, 1465, 1372
D-OAc-ロイシン tert-ブチルエステル (6.56 g, 28.5 mmol) のメタノール (30 mL) 溶液に、炭酸カリウム (19.68 g, 142.4 mmol) 水溶液 (60 mL )を加え、室温で1日間激しく攪拌した。反応終了後、メタノールを減圧留去し、残渣を分液ロートに移して、ジエチルエーテルで3回抽出した。合した有機層を、飽和食塩水で洗浄した後、無水硫酸ナトリウムで乾燥、減圧濃縮して無色油状物のD-O-ロイシン tert-ブチルエステル(4.35 g, 81.1
%)を得た。これは、精製すること無く次の反応に用いた。
・TLC ;Rf= 0.52 (A)
・1H-NMR (CDCl3); 0.94 (3H, d, J = 2.68 Hz, CH(CH 3 )2), 0.96 (3H, d, J = 2.44 Hz,
CH(CH 3 )2), 1.49-1.53 (11H, m, tert-Buand CHCH 2 CH), 1.81-1.95 (1H, m, CH(CH3)2),
2.74 (1H, d, J = 5.85 Hz, OH), 4.00-4.09 (1H, m, CH CH 2(CH3)2)
・13C-NMR (CDCl3); 21.59, 23.32, 24.49, 27.99, 43.59, 69.20, 82.23, 175.23
・[a]D- 6.90°(CHCl3, c 1.06, 14.7 ℃)
・IR; 3493, 2959, 2873, 1729, 1465, 1273
L-OAc-バリンは、D-OAc-ロイシンと同様の方法で合成した。すなわち、氷冷下でL-O-バリン 5 (5.00 g, 42.3 mmol ) に、塩化アセチル (15.0 mL,211 mmol) を滴下ロートから加えた。 TLCで原料の消失を確認した後、反応液を減圧濃縮した。この残渣に少量のトルエンを加え、減圧濃縮して残存する塩化アセチルをトルエンとのコエバポレーションにより除いた。この操作を3回繰り返して、濃縮残渣に無色油状物の 30 (6.73 g,quant) を得た。これは精製すること無く次の反応に用いた。
・TLC ;Rf = 0.63 (C)
・1H-NMR (CDCl3); 1.00-1.06 (6H, m, CH(CH 3 )2), 2.16 (3H, s, CH 3 CO), 2.20-2.33 (1H, m, CH(CH3)2), 4.89 (1H, d, J = 4.39 Hz, CHCH(CH3)2), 10.64 (1H, br, COOH)
・13C-NMR (CDCl3); 17.03, 18.70, 20.48, 29.86, 170.92, 175.61
L-OAc-バリン tert-ブチルエステルは,D-OAc-ロイシン tert -ブチルエステルと同様の方法で合成した。すなわち、L-OAc-バリン (6.73 g, 42.0 mmol)、tert-ブタノール ( 40 mL )、 Boc2O (9.17 g, 42.0 mmol) の混合物を室温下で攪拌し、ここにDMAP (1.03 g, 8.43 mmol) をゆっくりと加えた。室温で2時間攪拌した後、反応液を減圧濃縮し、濃縮残渣をシリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル)より精製して無色油状物のL-OAc-バリン tert-ブチルエステル (6.52 g, 71.8 %) を得た。
・TLC ; Rf = 0.57 (A)
・1H-NMR (CDCl3); 0.95-1.01 (6H, m, CH(CH 3 )2), 1.47 (9H, s, tert-Bu), 2.17 (3H, s, CH 3 CO), 2.16-2.24 (1H, m, CH(CH3)2), 4.72 (1H, d, J = 4.39 Hz, CHCH(CH3)2)
・13C-NMR (CDCl3); 17.12, 18.71, 20.64, 27.96, 29.93, 60.37, 81.83, 168.78, 170.77
・IR ; 2975, 2938, 2880, 1744, 1238
L-O-バリン tert-ブチルエステルは,L-O-ロイシン tert-ブチルエステルと同様に合成した。すなわち、L-OAc-バリン tert-ブチルエステル (6.52 g, 30.1 mmol) のメタノール (30 mL)溶液に、炭酸カリウム ( 20.83 g, 151.0 mmol ) 水溶液( 60 mL ) を加え、室温で1日間攪拌した。反応終了後、メタノールを減圧留去して、水層をジエチルエーテルで3回抽出した。合した有機層を飽和食塩水で洗浄、無水硫酸ナトリウムで乾燥し、減圧濃縮して無色油状物のL-O-バリン tert-ブチルエステル (3.87 g, 73.7 %) を得た。これは、これ以上精製すること無く次の反応に用いた。
・TLC ;Rf = 0.54 (A)
・1H-NMR (CDCl3); 0.86(3H, d, J = 6.83 Hz, CH(CH 3 )2), 1.02 (3H, d, J = 7.07 Hz, CH(CH 3 )2), 1.50(9H, s, tert-Bu), 3.92 (1H, d, J = 3.41, CHCH(CH3)2)
・13C-NMR (CDCl3); 15.72, 18.80, 25.58, 28.02, 32.08, 74.88, 82.31, 174.22
・[a]D+ 3.60°(MeOH, c 1.04, 15.1 ℃)
・IR ; 3518, 2970, 2879, 1726, 1465, 1259
ジデプシペプチドの合成
(12)Troc-L-グルタミン酸(OBn / AHA-OBn)-D-O-ロイシン tert-ブチルエステル ( 33)
氷冷下、N-保護L-グルタミン酸誘導体22 (1.12 mmol) およびD-ロイシン tert-ブチルエステル 29 (1.35 mmol) のジクロロメタン (10 mL) 溶液に、DMAP ( 0.34 mmol )、次いでDCC (1.68 mmol) をゆっくり加えた。この反応液を氷冷下で一晩攪拌した後、副成したDCUreaを吸引濾去して除き、濾液を減圧濃縮した。この濃縮残渣を酢酸エチルに溶かし、有機層を飽和炭酸水素ナトリウム水溶液、次いで飽和食塩水で洗浄して、無水硫酸ナトリウムで乾燥,減圧濃縮した。濃縮残渣をシリカゲルカラムクロマトグラフィー (ヘキサン/酢酸エチル) より精製して、目的とするジデプシペプチド 33 を得た。
・収率;35 %
・TLC ; Rf = 0.60 (F)
・1H-NMR (CDCl3); 0.91 (3H, d, J = 6.59 Hz), 0.94 (3H, d, J = 6.34 Hz), 1.45 (9H, s), 1.57-1.67 (2H, m), 1.70-1.81 (1H, m), 2.04-2.18 (1H, m,), 2.28-2.43 (1H, m), 2.47-2.61 (2H, m), 4.51-4.60 (1H, m), 4.67-4.76 (2H, m), 4.89-4.94 (1H, m), 5.13 (2H, s), 5.69 (1H, d, J = 8.29 Hz), 7.30-7.40 (5H, m)
・13C-NMR (CDCl3); 21.40, 23.01, 24.62, 26.97, 27.32, 27.88, 29.99, 39.46, 53.53, 66.59, 72.69, 74.45, 74.62, 82.43, 95.24, 128.22, 128.31, 128.57, 135.62, 154.04, 168.94, 172.38
・IR ; 3340, 2959, 1739, 1525, 1453, 1389, 1370, 1259, 1206
・収率;93 %
・TLC ; Rf= 0.42 (F)
・1H-NMR (CDCl3); 0.89-0.95 (6H, m, CH(CH 3 )2), 1.30-1.40 (2H, m, CH2), 1.46 (9H,
s, tert-Bu), 1.47-1.55 (2H, m, CH2), 1.59-1.80 (6H, m), 2.06-2.16 (1H, m, CHCH 2 CH2CO), 2.28-2.48 (5H, m), 3.16-3.28 (2H, m, CH2), 4.39-4.47 (1H, m, CHCH2CH(CH3)2), 4.66-4.77 (2H, m, CH 2 CCl3), 4.90-4.95 (1H, m, NH), 5.11 (2H, s, CH2Ph), 6.07-6.11 (2H, m, NH), 7.33-7.37 (5H, m, ArH)
・13C-NMR (CDCl3); 14.18, 21.05, 21.40, 23.03, 24.41, 24.55, 26.32, 27.90, 28.01, 29.07, 32.23, 34.04, 39.38, 39.57, 54.11, 60.39, 66.17, 72.49, 74.61, 82.57, 95.29, 128.20, 128.54, 129.01, 135.96, 154.37, 169.54, 170.86, 171.97, 173.38
・IR ; 3322, 2956, 2871, 1741, 1653, 1537, 1239, 735
氷冷下、33 (0.85 mmol) のジクロロメタン (3.0 mL) 溶液に、TFA (3.0 mL) をゆっくり加え、氷冷下で30分間、次いで室温下で1.5時間攪拌した。TLCで反応の終了を確認した後、反応液を減圧濃縮して淡黄色油状物の34 (quant.) を得た。これは、精製すること無く次の反応に用いた。
・収率;quant
・TLC ; Rf = 0.56 (C)
・1H-NMR (CDCl3); 0.92 (3H, d, J = 6.10 Hz), 0.95 (3H, d, J = 6.34 Hz), 1.65-1.78 (2H, m), 1.80-1.91 (1H, m), 2.02-2.16 (1H, m,), 2.26-2.38 (1H, m), 2.41-2.60 (2H, m), 4.49-4.58 (1H, m), 4.62-4.78 (2H, m), 5.06-5.12 (1H, m), 5.13 (2H, s), 5.74 (1H, d, J = 8.05 Hz), 7.29-7.40 (5H, m)
・13C-NMR (CDCl3); 21.29, 22.96, 24.62, 27.11, 29.97, 39.34, 53.54, 66.70, 71.61, 74.70, 95.19, 128.26, 128.36, 128.60, 135.55, 154.19, 170.84, 172.50
・IR ; 3419, 2959, 1736, 1643, 1521, 1452, 1391, 1210, 1099
・収率;quant
・TLC ; Rf = 0.52 (C)
・1H-NMR (CDCl3); 0.88-0.99 (6H, m, CH(CH 3 )2), 1.29-1.40 (2H, m, CH2), 1.44-1.56
(2H, m, CH2), 1.60-1.67 (2H, m, CH2), 1.68-1.79 (2H, m, CH2), 1.82-1.88 (1H, m, CH(CH3)2), 2.10-2.19 (1H, m, CHCH 2 CH2CO), 2.19-2.30 (1H, m, CHCH 2 CH2CO), 2.35-2.42 (4H, m, CH2), 3.19-3.28 (2H, m, CH2), 4.39-4.47 (1H, m, CHCH2CH(CH3)2), 4.67-4.77 (2H, m, CH 2 CCl3), 5.09-5.11 (1H, m, NH), 5.12 (2H, s, CH2Ph), 6.29 (1H, d,
J = 7.56 Hz, NH), 6.45-6.52 (1H, m, NH), 7.33-7.39 (5H, m, ArH), 8.77 (1H, br, COOH)
・13C-NMR (CDCl3); 21.30, 23.03, 24.34, 24.58, 26.17, 28.01, 28.67, 32.07, 34.05, 39.36, 39.53, 54.08, 66.47, 71.82, 74.64, 95.22, 128.21, 128.31, 128.58, 135.66, 154.56, 170.81, 172.67, 173.18, 174.17
・IR ; 3351, 3062, 2957, 2871, 1734, 1630, 1539, 1453, 1386, 1211, 1099
氷冷下、炭酸ナトリウム (21.45 g, 202 mmol) 水溶液 (225 mL) に市販のD-アラニン (6.00 g, 73.5 mmol) を溶解し、ここにbenzyl chloroformate (Z-Cl ) (10.5 mL, 73.5 mmol) のジオキサン (60 mL) 溶液をゆっくり滴下した。滴下終了後、反応液を室温に戻し一晩攪拌を続けた。反応液を分液ロートに移し、過剰のZ-Clをジエチルエーテル抽出で除去した。水層にクエ BR>梼_を加えてpH 3に調整した後、酢酸エチルで3回抽出した。合した有機層を飽和食塩水で1回洗浄し、有機層を無水硫酸ナトリウムで乾燥、減圧濃縮した後、濃縮残渣を酢酸エチル-ヘキサンより再結晶化して無色結晶のZ-D-アラニン (13.77 g, 91.6 %) を得た。
・mp ; 82.9 ℃
・1H-NMR (CDCl3); 1.47(3H,d, J = 7.32 Hz, CH 3 ), 4.38-4.48(1H, m, CHCH3), 5.13(2H, s, CH 2 Ph), 5.29(1H, br, NH), 7.30-7.38 (5H, m, ArH)
・13C-NMR (CDCl3); 18.36, 49.52, 67.22, 128.10, 128.25, 128.53, 136.05, 155.92, 177.45
・IR ; 3349, 3046, 1719, 1539, 1252
氷冷下、L-O-バリン tert-ブチルエステル 32 (2.50 g, 14.3 mmol) およびZ-D-アラニン
(3.52 g, 15.8 mmol) のジクロロメタン (30 mL) 溶液に、DMAP (0. 35 g,2.9 mmol)、次いでDCC (3.70 g,17.9 mmol) をゆっくり加えた。この反応液を氷冷下で一晩攪拌した後、副成したDCUreaを吸引濾過により除き、濾液を減圧濃縮した。この濃縮残渣を酢酸エチルに溶かし、有機層を飽和炭酸水素ナトリウム水溶液、次いで飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥、減圧濃縮した。この濃縮残渣をシリカゲルカラムクロマトグラフィー (ヘキサン/酢酸エチル) より精製して、無色油状物の35 (4.26 g, 78.3 %) を得た。
・TLC ; Rf = 0.36 (A)
・1H-NMR (CDCl3); 0.92-1.02 (6H, m, CH(CH 3 )2), 1.46 (9H, s, tert-Bu), 1.47 (3H, d, J =7.07 Hz, CHCH 3 ), 2.18-2.29 (1H, m, CH(CH3)2), 4.46-4.57 (1H, m, CHCH3), 4.75 (1H, d, J = 4.15 Hz, CHCH(CH3)2), 5.11 (2H, s, CH 2 Ph), 5.35 (1H, d, J = 7.07 Hz, NH), 7.29-7.40 (5H, m, ArH)
・13C-NMR (CDCl3); 16.93, 18.73, 27.93, 30.00, 49.74, 66.84, 82.22, 128.11, 128.13, 128.50, 136.23, 155.46, 168.05, 172.34
・IR ; 3342, 2974, 2937, 2879, 1734, 1528, 1254
・[a]D-18.04°(CHCl3, c 0.875, 15.7 ℃)
水素添加用フラスコに、35 (1.96 g, 5.17 mmol)、メタノール (30 mL)、TFA (0.46 mL, 6.2 mmol) および10% パラジウム炭素 (100 mg) の混合物を入れ、水素気流(3気圧)下、室温で3時間攪拌した。TLCで反応の進行を確認した後、触媒を濾去、濾液を減圧濃縮し、濃縮残渣をシリカゲルカラムクロマトグラフィー (クロロホルム/メタノール) より精製して、淡褐色油状物の 36 (1.65 g, 93.3 %) を得た。
・TLC ; Rf = 0.34 (B)
・1H-NMR (CDCl3); 0.96-1.04 (6H, m, CH(CH 3 )2), 1.36 (3H, d, J =8.54 Hz, CHCH 3 ),1.47 (9H, s, tert-Bu), 2.20-2.29 (1H, m, CH(CH3)2), 3.66 (1H, q,J = 7.07 Hz, CHCH3), 4.76 (1H, d, J = 4.39 Hz, CHCH(CH3)2)
・13C-NMR (CDCl3); 16.99, 18.80, 20.29, 27.97, 28.01, 30.02, 32.07, 49.97, 82.01, 168.52, 176.24
・IR ; 3445, 2977, 1747, 1677, 1537, 1464, 1432, 1395, 1371, 1330, 1204
テトラデプシペプチドの合成
(17)Troc-L-グルタミン酸(OBn / AHA-OBn)-D-O-ロイシン-D-アラニン-L-O-バリン tert-ブチルエステル ( 37 )
氷冷下、N末端が保護されたジデプシペプチド36・TFA塩 (289 mg、 0.84 mmol) のアセトニトリル (5 mL) 溶液に、DIPEA (0.15 mL、 0.84 mmol) を加えて中和した後、C末端が保護されたジデプシペプチド34 (0.84 mmol) のアセトニトリル (5 mL) 溶液を加え、次いでHBTU (352 mg、 0.93 mmol) および HOBt (114 mg、 0.84 mmol) を加えた。反応液を室温に戻して一晩攪拌した後、反応液を減圧濃縮した。この濃縮残渣を酢酸エチルに溶解し、酢酸エチル層を10%クエン酸水溶液、飽和炭酸水素ナトリウム水溶液、および飽和食塩水で、順次、洗浄して無水硫酸ナトリムで乾燥、減圧濃縮した。これをシリカゲルカラムクロマトグラフィー (ヘキサン/酢酸エチル) より精製して淡黄色油状の37を得た。
・収率;75 %
・TLC ; Rf = 0.64 (F)
・1H-NMR (CDCl3); 0.85-1.00 (12H, m), 1.45 (9H, s), 1.48 (3H, d, J = 7.32 Hz), 1.60-1.83 (3H, m), 1.99-2.15 (1H, m), 2.15-2.36 (2H, m), 2.41-2.62 (2H, m), 4.43-4.52 (1H, m), 4.60-4.81 (4H, m), 5.14 (2H, s), 5.27 (1H, dd, J = 5.61 Hz, J = 7.56 Hz), 5.98 (1H, d, J = 7.56 Hz), 6.83 (1H, d, J = 7.56 Hz), 7.30-7.40 (5H, m)
・13C-NMR (CDCl3); 16.88, 17.72, 18.69, 21.42, 23.09, 24.47, 26.52, 27.94, 30.02, 40.50, 47.95, 53.69, 66.73, 73.49, 74.74, 82.33, 95.18, 128.28, 128.38, 128.59, 135.49, 154.50, 168.28, 169.22, 170.47, 171.91, 172.37
・IR ; 3421, 2964, 1739, 1674, 1538, 1455, 1391, 1370, 1256
・収率 55 %
・TLC ; Rf= 0.31 (F)
・1H-NMR (CDCl3); 0.85-1.00 (12H, m),1.30-1.40 (2H, m), 1.45 (9H, s), 1.49 (3H, d, J = 7.32 Hz), 3.19-3.29 (1H, m), 4.39-4.46 (1H, m), 4.62-4.80 (4H, m), 5.11 (2H, s), 5.23 (1H, dd, J = 4.88 Hz, J = 9.02 Hz), 6.03-6.11 (1H, m), 6.59 (1H, d,
J = 7.07 Hz), 7.00 (1H, d, J = 7.56 Hz), 7.30-7.40 (5H, m)
・13C-NMR (CDCl3); 16.89, 17.59, 18.69, 21.39, 23.12, 24.33, 24.41, 26.25, 26.92, 27.92, 28.96, 30.00, 31.97, 33.99, 39.45, 40.46, 48.12, 54.22, 66.17, 73.24, 74.66, 77.68, 82.28, 95.27, 128.17, 128.22, 128.54, 128.55, 135.90, 154.72, 168.24, 169.68, 170.68, 171.96, 172.26, 173.44
・IR ; 3335, 2962, 1757, 1680, 1538, 1455, 1108, 736
CおよびN-末端が保護されたテトラデプシペプチド 37 (0.24 mmol) の90%酢酸溶液 (3 mL ) に、亜鉛 (310.6mg、 4.74 mmol) を加えて、室温で一日攪拌した。反応終了後、反応液に多量の水を加え、酢酸エチルで3回抽出した。合した有機層を水、飽和炭酸水素ナトリウム水溶液、および飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥、減圧濃縮して38 を得た。
・収率 ; quant
・TLC ; Rf = 0.53 (B)
・1H-NMR (CDCl3); 0.78-1.03 (12H, m), 1.40-1.50 (12H, m), 1.60-1.82 (3H, m), 2.05-2.32 (3H, m), 2.31-2.59 (2H, m), 4.33-4.45 (1H, m), 4.65-4.81 (2H, m), 5.13 (2H, s)、 5.18-5.25 (1H, m), 6.57 (1H, d, J = 7.56 Hz), 6.88 (1H, d, J = 7.32 Hz), 7.29-7.38 (5H, m)
・13C-NMR (CDCl3); 16.94, 18.20, 18.74, 21.53, 23.13, 24.53, 27.96, 27.97, 30.05, 40.64, 47.72, 55.22, 66.39, 72.93, 77.24, 77.83, 82.38, 126.99, 128.20, 128.57, 135.83,168.13, 168.97, 169.65, 172.22, 172.89
・IR ; 3346, 2965, 2938, 2875, 1740, 1679, 1538, 1455, 1391, 1370
・収率 96 %
・TLC ; Rf = 0.42 (C)
・1H-NMR (CDCl3); 0.82-1.02 (12H, m), 1.30-1.39 (2H, m), 1.42-1.55 (15H, m), 1.58-1.84 (5H, m), 1.87-1.99 (1H, m), 2.14-2.29 (2h, m), 2.29-2.42 (4H, m), 3.13-3.29 (2H, m), 3.63-3.76 (1H, m), 4.70 (1H, d, J = 7.56 Hz), 4.73 (1H, d, J =4.39 Hz), 5.11 (2H, s), 5.23 (1H、 dd, J = 3.90 Hz, J = 9.51 Hz), 6.12-6.24 (1H, m), 7.04 (1H, d, J = 7.56 Hz), 7.29-7.38 (5H, m)
・13C-NMR (CDCl3); 14.16, 16.96, 18.00, 18.69, 21.47, 23.10, 24.42, 24.45, 26.32, 27.90, 29.14, 30.01, 32.42, 34.02, 39.25, 40.64, 47.76, 60.39, 66.14, 73.02, 82.39, 128.17、 128.20, 128.53, 135.91, 168.19, 169.73, 172.15, 172.29, 173.41
・IR ; 3317, 3068, 2962, 2873, 1739, 1663, 1637, 1545, 1456, 1370, 1163
ドデカデプシペプチド(前駆体)の合成
(19) Boc-L-バリン-D-O-ロイシン-D-アラニン-L-O-バリン-L-バリン- D-O-ロイシン-D-アラニン-L-O-バリン- L-グルタミン酸(OBn / AHA-OBn)-D-O-ロイシン-D-アラニン-L-O-バリン tert-ブチルエステル ( 39 )
氷冷下、C末端が保護されたテトラデプシペプチド38 (0.155 mmol) および N末端が保護されたオクタデプシペプチド 15 (137 mg、 0.155 mmol) のアセトニトリル(5 mL) 溶液を入れ、ここに、DIPEA (27.0 μL、 0.155 mmol)、HOAt(21.1 mg、 0.155 mmol)および HATU (88.2 mg、 0.232 mmol) を加えた。反応液を室温に戻して一晩攪拌した後、減圧濃縮して、残渣を酢酸エチルに溶解し、酢酸エチル層を10%クエン酸水溶液、飽和炭酸水素ナトリウム水溶液および飽和食塩水で、順次、洗浄した。この有機層を無水硫酸ナトリウムで乾燥、減圧濃縮し、残渣をシリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル=3:2)より精製して無色油状物の 39 を得た。
・収率 40 %
・TLC ; Rf = 0.64 (F)
・1H-NMR (CDCl3); 0.74-1.09 (48H, m), 1.32-1.53 (27H, m), 1.60-1.86 (9H, m), 1.92-2.04 (1H, m), 2.13-2.26 (2H, m), 2.27-2.44 (4H, m), 2.45-2.52 (2H, m), 3.84 (1H, dd, J = 5.85 Hz, J = 7.56 Hz), 4.01-4.16 (2H, m), 4.27 (1H, t, J = 7.56 Hz), 4.48-4.56 (1H, m), 4.60 (1H, t, J = 7.56 Hz), 4.65 (1H, d, J = 4.15 Hz), 4.97 (1H, d, J = 2.93 Hz), 5.07 (1H, d, J = 2.68 Hz), 5.27 (1H, dd, J = 3.90 Hz, J = 8.87 Hz), 7.28-7.37 (5H, m), 7.74 (1H, d, J = 7.32 Hz), 7.87 (1H, d, J = 7.32 Hz), 7.96 (1H, d, J = 5.85 Hz), 8.10 (1H, d, J = 7.81 Hz), 8.25 (1H, d, J = 6.10 Hz)
・13C-NMR (CDCl3); 13C-NMR (CDCl3); 16.18, 16.34, 16.56, 17.02, 17.57, 18.67, 18.95, 19.00, 19.06, 19.22, 19.30 20.78, 20.89, 21.17, 23.12, 23.13, 23.36, 24.29, 24.39, 24.42, 26.20, 27.93, 28.26, 29.66, 29.80, 29.98, 30.08, 30.19, 30.41, 40.53, 40.65, 40.76, 48.25, 49.43, 49.63, 52.06, 58.97, 60.40, 66.31, 72.69, 72.75, 73.04, 77.56, 78.65, 79.00, 81.00, 81.79, 128.09, 128.24, 128.47, 135.93, 156.56, 168.44, 169.99, 170.15, 170.44, 170.90, 170.93, 171.92, 172.19、 172.26, 172.44, 172.50
・IR ; 3316, 2965, 2876, 1748, 1658, 1538, 1460, 1369, 1158
・収率 73.5 %
・TLC ; Rf= 0.58 (B)
・1H-NMR (CDCl3); 0.82-1.09 (48H, m), 1.39-1.53 (33H, m), 1.53-1.89 (11H, m), 1.93-2.05 (1H, m), 2.10-2.44 (9H, m), 3.09-3.28 (2H, m), 3.84 (1H, dd, J = 5.85 Hz, J = 7.56 Hz), 4.03-4.19 (2H, m), 4.30 (1H, t, J = 7.56 Hz), 4.37-4.48 (1H, m), 4.59-4.67 (2H, m), 4.97 (1H, d, J= 3.17 Hz), 5.02 (1H, d, J = 2.93 Hz), 5.07-5.15 (4H, m), 5.20-5.30 (1H, m), 6.53 (1H, s), 7.28-7.40 (5H, m), 7.66 (1H, d, J = 7.32 Hz,), 7.87 (1H, d, J = 7.56 Hz,), 7.94-8.01 (2H, m), 8.29 (1H, d, J = 6.10 Hz)
・13C-NMR (CDCl3); 16.22, 16.33, 16.52, 17.07, 17.62, 18.63, 18.90, 18.96, 19.05, 19.20, 20.77, 20.85, 21.14, 23.06, 23.11, 23.33, 24.29, 24.37, 24.56, 26.46, 27.46, 27.90, 27.93, 28.24, 29.28, 29.69, 29.78, 29.97, 30.03, 30.16, 32.48, 34.13, 39.36, 40.50, 40.66, 40.75, 48.04, 49.28, 49.63, 52.21, 58.84, 60.39, 66.05, 72.70, 72.77, 73.06, 77.20, 77.54, 77.77, 78.82, 78.98, 80.96, 81.93, 128.13, 128.18, 128.50, 136.03, 156.51, 168.31, 169.85, 170.35, 170.59, 170.86, 170.91, 170.98, 171.87, 172.14, 172.23, 172.47, 173.45
・IR ; 3319, 2965, 2875, 1748, 1656, 1539, 1460, 1370, 1158, 747
氷冷下、39 (69 μmol) のジクロロメタン (2 mL) 溶液に、TFA ( 2 mL) をゆっくり加え、1時間、氷冷下で攪拌を続けた。TLCで反応の進行を確認した後、反応液にトルエンを加え減圧濃縮した。TFAを完全に取り除くために、濃縮残渣にトルエンを加え共沸留去した。この操作を3回繰り返して行い、淡黄色固体の40を得た。これは、精製すること無く次の環化反応に用いた。
40a (R = OBn) ;
・収率;94 %
・TLC ; Rf = 0.43 (B)
・1H-NMR (CDCl3); 0.83-1.09 (48H, m), 1.39 (3H, d, J = 7.32 Hz), 1.47 (3H, d, J = 7.07 Hz), 1.51 (3H, d, J = 7.56 Hz), 1.58-1.84 (9H, m), 2.10-2.41 (9H, m), 4.10-4.25 (2H, m), 4.26-4.38 (2H, m), 4.57-4.66 (1H, m), 4.73-4.79 (1H, m), 4.86 (1H, d, J = 3.42 Hz), 4.93 (1H, d, J = 2.93 Hz), 5.02 (1H, s), 5.05-5.17 (3H, m), 5.27 (1H, dd, J = 4.39 Hz, J = 7.56 Hz), 7.31-7.41 (5H, m), 7.64 (2H, d, J = 8.54 Hz), 7.74 (1H, d, J= 3.17 Hz), 7.77 (1H, d, J = 7.81 Hz), 8.32 (1H,d, J = 5.61 Hz), 8.64 (1H, d, J = 5.85 Hz)
・13C-NMR (CDCl3); 14.98, 15.63, 16.31, 16.70, 17.05, 17.23, 17.44, 17.71, 18.41, 18.54, 18.66, 18.93, 19.12, 19.58, 20.95, 21.11, 21.62, 22.99, 23.10, 23.16, 23.22, 24.33, 24.48, 24.52, 27.84, 29.66, 30.35, 30.54, 40.03, 40.14, 40.38, 50.09, 53.42, 58.74, 66.56, 73.94, 75.13, 78.02, 79.18, 79.24, 82.03, 128.23, 128.58, 128.95, 135.53, 169.15, 170.45, 171.34, 171.54, 171.82, 171.94, 172.12, 172.36, 173.42
・IR ; 3296, 3068, 2965, 2870, 1749, 1661, 1543, 1466, 1372, 1202
・収率;quant
・TLC ; Rf = 0.36 (B)
・1H-NMR (CDCl3); 0.80-1.09 (48H, m), 1.24-1.33 (11H, m), 1.36-1.42 (4H, m), 1.43-1.52 (3H, m), 1.55 (2H, d, J = 7.32 Hz), 1.58-1.88 (9H, m), 2.12-2.40 (9H, m), 3.00-3.14 (2H, m), 3.16-3.30 (1H, m), 3.97 (1H, d, J = 4.63 Hz), 4.05 (1H, dd, J = 7.07 Hz, J = 10.49 Hz), 4.60 (1H, t, J = 7.56 Hz), 4.65-4.79 (4H, m), 4.83 (1H, d, J = 3.41 Hz), 4.88 (1H, d, J = 2.68 Hz), 5.02-5.09 (2H, m), 5.11 (2H, s), 5.33 (1H, dd, J = 3.41 Hz, J = 9.02 Hz), 6.25 (1H, s), 7.29-7.39 (5H, m), 7.54-7.66 (2H, m), 7.82 (1H, d, J= 7.56 Hz), 8.58 (1H, d, J = 7.32 Hz), 9.27 (1H, s)
・13C-NMR (CDCl3); 15.37, 15.74, 16.60, 16.74, 16.86, 17.02, 17.39, 17.84, 18.39, 18.46, 18.86, 19.18, 19.38, 20.99, 21.17, 21.28, 22.94, 23.00, 23.24, 24.38, 24.44, 24.49, 26.29, 28.47, 29.04, 29.60, 29.65, 29.83, 30.53, 32.26, 34.00, 39.60, 40.13, 40.40, 47.67, 49.33, 53.17, 58.71, 66.22, 73.03, 75.19, 77.21, 78.90, 128.18, 128.21, 128.24, 128.55, 129.01, 135.89, 169.18, 170.62, 170.78, 171.03, 171.59, 171.63, 172.24, 172.69, 173.26, 173.46
・IR ; 3300, 3081, 2965, 2876, 1748, 1657, 1545, 1462, 1374, 1203
E-セレウリドおよびEAHA-セレウリド(環化反応)
(22)E-セレウリド-OBn ( 41a ) および EAHA-セレウリド-OBn ( 41b )
前駆体 40 の環化反応は、セレウリド合成の場合と同様の方法で行った。すなわち、アルゴン置換した反応容器に、ジフェニルホスホリルアジド(DPPA) (9.8 μL, 45.5 μmol)を、無水N,N- ジメチルホルムアミド( 12 mL )に溶解し、次いで、N,N-ジイソプロピルエチルアミン (15.7 μL, 90 μmol) をゆっくり加えて、A液を調製した。
・TLC ; Rf = 0.69 (F)
・1H-NMR (CDCl3); 0.78-1.03 (48H, m), 1.40-1.48 (9H, m), 1.58-1.84 (11H, m), 2.10-2.60 (9H, m), 4.00-4.10 (2H, m), 4.25-4.60 (3H, m), 4.91-5.01 (2H, m), 5.02 (1H, d, J = 3.17 Hz), 5.10-5.14 (3H, m), 5.23 (1H, dd, J = 3.90 Hz, J = 5.37 Hz), 5.26-5.33 (2H, m), 7.31-7.37 (5H, m), 7.62 (1H, d, J = 6.59 Hz), 7.74-7.80 (3H, m), 7.84 (1H, d, J= 5.85 Hz), 7.96 (1H, d, J = 7.56 Hz)
・13C-NMR (CDCl3); 15.72, 15.80, 16.77, 16.89, 18.46, 18.52, 18.65, 19.26, 19.32, 21.11, 21.20, 21.73, 23.01, 23.32, 24.32, 24.36, 24.51, 28.52, 28.72, 30.28, 30.39, 30.47, 30.57, 40.39, 48.57, 48.79, 49.03, 51.78, 59.41, 59.55, 66.42, 72.58, 72.78, 73.30, 78.47, 78.64, 78.77, 128.20, 128.23, 128.53, 169.92, 170.42, 170.63, 171.02, 171.06, 171.33, 171.43, 171.53, 171.74, 171.84, 172.04, 172.18
・IR ; 3433, 3310, 2964, 2872, 1742, 1654, 1538, 1463, 1389, 1371, 1198, 1160
・[a]D + 7.17°(CHCl3, c 1.20 , 25 ℃)
・MALDI/TOFMS; 1295 [M + Na]+, 1311 [M + K]+
・TLC ; Rf= 0.23 (F)
・mp ; 64.7 ℃
・1H-NMR (CDCl3); 0.82-1.01 (42H, m), 1.04 (3H, d, J = 6.34 Hz), 1.06 (3H, d, J = 6.10 Hz), 1.29-1.39 (2H, m), 1.40-1.54 (11H, m), 1.60-1.72 (6H, m), 1.72-1.82 (4H, m), 1.90-2.00 (1H, m), 2.03-2.14 (2H, m), 2.15-2.42 (9H, m), 3.09-3.19 (1H,
m), 3.21-3.33 (1H, m), 4.03-4.12 (2H, m), 4.26-4.40 (2H, m), 4.41-4.53 (2H, m), 4.97 (1H, d, J = 3.17 Hz), 5.02-5.05 (2H, m), 5.11 (2H, s), 5.15-5.22 (1H, m), 5.25-5.33 (2H, m), 6.42-6.47(1H, m), 7.29-7.40 (5H, m), 7.63-7.77 (3H, m), 7.84 (1H, d, J = 7.32 Hz), 7.91 (1H, d, J = 7.07 Hz)
・13C-NMR (CDCl3); 15.91, 16.70, 16.99, 18.47, 18.56, 19.07, 19.21, 19.30, 19.35, 21.04, 21.36, 21.50, 23.07, 23.27, 23.34, 24.34, 24.52, 26.41, 28.61, 28.74, 29.29, 30.29, 30.35, 30.49, 32.51, 34.09, 39.34, 40.27, 40.53, 48.31, 48.62, 48.90, 52.38, 59.10, 59.59, 66.11, 72.82, 73.17, 78.20, 78.61, 78.89, 128.16, 128.52, 135.97, 170.31, 170.43, 170.62, 170.89, 171.06, 171.25, 171.53, 171.68, 171.76, 173.36
・IR ; 3298, 2963, 1744, 1657, 1538, 1461
・MALDI/TOFMS; 1409 [M + Na]+, 1425 [M + K]+
水素添加用フラスコに、41 (20 mg)、メタノール (5 mL)および10% パラジウム炭素 (2 mg) の混合物を入れ、水素気流(3気圧)下、室温で3時間攪拌した。TLCで反応の進行を確認した後、触媒を濾去、濾液を減圧濃縮しE-セレウリドおよびEAHA-セレウリドを得た。
E-セレウリド ;
・収率;quant
・TLC ; Rf = 0.39 (B)
・1H-NMR (CDCl3); 0.78-1.12 (48H, m), 1.40-1.54 (9H, m), 1.60-1.90 (8H, m), 2.06-2.16 (1H, m), 2.17-2.42 (6H, m), 2.42-2.63 (3H, m), 4.06-4.15 (2H, m), 4.25-4.35 (1H, m), 4.35-4.43 (1H, m), 4.43-4.56 (2H, m), 4.70-4.82 (1H, m), 4.92-5.04 (1
H, m), 5.13-5.31 (1H, m), 6.82(1H, s), 7.60-7.92 (6H, m), 5.07 (1H, d, J = 3.17 Hz), 5.09-5.15 (1H, m), 5.17-5.25 (1H, m), 5.25-5.33 (1H, m), 7.34 (1H, d, J = 5.85 Hz), 7.43-7.50 (1H, m), 7.60-7.82 (4H, m), 8.03 (1H, s)
・13C-NMR (CDCl3); 16.28, 16.48, 16.65, 16.85, 16.94, 18.52, 18.56, 18.73, 19.05, 19.17, 19.24, 21.08, 21.34, 21.40, 21.52, 23.08, 23.22, 23.29, 24.39, 24.61, 24.64, 27.93, 28.73, 29.70, 30.12, 30.48, 40.44, 40.50, 48.26, 48.46, 48.57, 52.4
8, 59.42, 72.71, 72.88, 73.57, 77.22, 77.92, 78.22, 78.53, 170.00, 170.11, 170.84, 171.16, 171.22, 171.34, 171.45, 171.54, 171.95
・IR ; 3435, 3316, 2964, 1742, 1654, 1538, 1466, 1383, 1198
・MALDI/TOFMS; 1205 [M + Na]+, 1221 [M + K]+
・収率 ; quant
・TLC ; Rf= 0.32 (B)
・1H-NMR (CDCl3); 0.75-1.00 (42H, m), 1.06 (6H, d, J = 5.85 Hz), 1.34-1.58 (13H,
m), 1.58-1.86(11H, m), 1.95-2.10 (1H, m), 2.17-2.42 (10H, m), 3.09-3.26 (1H, m), 3.26-3.44 (1H, m), 4.00-4.12 (1H, m), 4.12-4.22 (1H, m), 4.27-4.40 (2H, m),4.40-4.50 (2H, m), 4.97 (1H, d, J = 3.17 Hz), 4.99-5.08 (2H, m), 5.13-5.31 (1H, m), 6.82(1H, s), 7.60-7.92 (6H, m)
・IR ; 3304, 2963, 2938, 2875, 1743, 1655, 1539, 1466, 1373, 1197
・MALDI/TOFMS ; 1319 [M + Na]+, 1335 [M + K]+
Claims (7)
- 請求項2記載のジデプシペプチドを調製する工程を含む、請求項4記載の製造方法。
- さらに、請求項3記載のデプシペプチドを調製する工程を含む、請求項5記載の製造方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020147022990A KR101951379B1 (ko) | 2012-02-08 | 2013-02-07 | 세레울라이드 및 그 유도체의 제조 방법, 세레울라이드 제조를 위한 중간체 및 세레울라이드 유도체 |
SG11201404764VA SG11201404764VA (en) | 2012-02-08 | 2013-02-07 | Method for producing cereulide and derivative thereof, intermediate for production of cereulide, and cereulide derivative |
JP2013557569A JP5947821B2 (ja) | 2012-02-08 | 2013-02-07 | セレウリドおよびその誘導体の製造方法、セレウリド製造の為の中間体ならびにセレウリド誘導体 |
US14/377,748 US9422341B2 (en) | 2012-02-08 | 2013-02-07 | Method for producing cereulide and derivative thereof, intermediate for production of cereulide, and cereulide derivative |
EP13746354.3A EP2813513B1 (en) | 2012-02-08 | 2013-02-07 | Method for producing cereulide and derivative thereof, intermediate for production of cereulide, and cereulide derivative |
HK15100111.7A HK1199884A1 (en) | 2012-02-08 | 2015-01-06 | Method for producing cereulide and derivative thereof, intermediate for production of cereulide, and cereulide derivative cereulide cereulide cereulide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-024722 | 2012-02-08 | ||
JP2012024722 | 2012-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013118823A1 true WO2013118823A1 (ja) | 2013-08-15 |
Family
ID=48947580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/052870 WO2013118823A1 (ja) | 2012-02-08 | 2013-02-07 | セレウリドおよびその誘導体の製造方法、セレウリド製造の為の中間体ならびにセレウリド誘導体 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9422341B2 (ja) |
EP (1) | EP2813513B1 (ja) |
JP (1) | JP5947821B2 (ja) |
KR (1) | KR101951379B1 (ja) |
HK (1) | HK1199884A1 (ja) |
SG (1) | SG11201404764VA (ja) |
WO (1) | WO2013118823A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021100945A (ja) * | 2015-03-06 | 2021-07-08 | ステルス バイオセラピューティックス コープ | 薬学的に適切なペプチドを調製するための方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097821A1 (fr) | 2002-05-17 | 2003-11-27 | Bio Control Institute Limited | Synthase de cereulide produite par bacillus cereus, gene codant pour celle-ci et procede de detection de cereulide |
WO2006006256A1 (ja) | 2004-09-24 | 2006-01-19 | Kobayashi Pharmaceutical Co., Ltd. | 消臭剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2155871A1 (en) * | 1993-02-19 | 1994-09-01 | Makoto Ohyama | Derivatives of cyclodepsipeptide pf 1022 |
KR20000016536A (ko) * | 1996-06-25 | 2000-03-25 | 쇼다 오사무 | 환상 뎁시펩티드 및 이를 유효성분으로 하는 의약 |
JP2006006256A (ja) | 2004-06-29 | 2006-01-12 | Meiji Milk Prod Co Ltd | 嘔吐型Bacilluscereusの迅速検出法 |
WO2008098199A2 (en) | 2007-02-08 | 2008-08-14 | Uwm Research Foundation, Inc. | Sequences for fk228 biosyntnesis and methods of synthesizing fk228 and fk228 analogs |
EP2192109B1 (en) * | 2007-09-28 | 2013-09-04 | Daiichi Sankyo Company, Limited | Bicyclic -amino acid derivative |
KR101119561B1 (ko) * | 2009-01-02 | 2012-03-07 | 중앙대학교 산학협력단 | 고리형 펜타뎁시펩타이드를 생산하는 푸사리움속 미생물 |
-
2013
- 2013-02-07 JP JP2013557569A patent/JP5947821B2/ja active Active
- 2013-02-07 KR KR1020147022990A patent/KR101951379B1/ko active IP Right Grant
- 2013-02-07 US US14/377,748 patent/US9422341B2/en active Active
- 2013-02-07 WO PCT/JP2013/052870 patent/WO2013118823A1/ja active Application Filing
- 2013-02-07 SG SG11201404764VA patent/SG11201404764VA/en unknown
- 2013-02-07 EP EP13746354.3A patent/EP2813513B1/en active Active
-
2015
- 2015-01-06 HK HK15100111.7A patent/HK1199884A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097821A1 (fr) | 2002-05-17 | 2003-11-27 | Bio Control Institute Limited | Synthase de cereulide produite par bacillus cereus, gene codant pour celle-ci et procede de detection de cereulide |
WO2006006256A1 (ja) | 2004-09-24 | 2006-01-19 | Kobayashi Pharmaceutical Co., Ltd. | 消臭剤 |
Non-Patent Citations (6)
Title |
---|
"Protective Groups in Organic Synthesis", 1999, WILEY-INTERSCIENCE |
BIESTA-PETERS E. G. ET AL.: "Quantification of the Emetic Toxin Cereulide in Food Products by Liquid Chromatography-Mass Spectrometry Using Synthetic Cereulide as a Standard.", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 76, no. 22, 2010, pages 7466 - 7472, XP055161397 * |
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 23, 1995, pages 2855 - 2858 |
ISOBE M. ET AL.: "Synthesis and Activity of Cereulide, a Cyclic Dodecadepsipeptide lonophore as Emetic Toxin from Bacillus cereus.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 23, 1995, pages 2855 - 2858, XP004135181 * |
SYNTHESIS, 2009, pages 2184 - 2204 |
YOICHI KAMATA ET AL.: "Cereus-kin Oyobi Cereus- kin ga Sansei suru Oto Dokuso ni Kansuru Kenkyu", SHOKUHINCHU NO DOKUSO SANSEI SHOKUCHUDOKU SAIKIN OYOBI DOKUSO NO CHOKUSETSU SHIKENHO NO KENKYU HEISEI 20 TO 22 NENDO SOGO KENKYU HOKOKUSHO, March 2011 (2011-03-01), pages 11 - 36, XP008174904 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021100945A (ja) * | 2015-03-06 | 2021-07-08 | ステルス バイオセラピューティックス コープ | 薬学的に適切なペプチドを調製するための方法 |
JP7450572B2 (ja) | 2015-03-06 | 2024-03-15 | ステルス バイオセラピューティクス インコーポレイテッド | 薬学的に適切なペプチドを調製するための方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20140119125A (ko) | 2014-10-08 |
US20150183831A1 (en) | 2015-07-02 |
US9422341B2 (en) | 2016-08-23 |
HK1199884A1 (en) | 2015-07-24 |
EP2813513B1 (en) | 2019-07-03 |
SG11201404764VA (en) | 2014-10-30 |
JPWO2013118823A1 (ja) | 2015-05-11 |
EP2813513A1 (en) | 2014-12-17 |
KR101951379B1 (ko) | 2019-02-22 |
JP5947821B2 (ja) | 2016-07-06 |
EP2813513A4 (en) | 2015-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guichard et al. | Preparation of N‐Fmoc‐protected β2‐and β3‐amino acids and their use as building blocks for the solid‐phase synthesis of β‐peptides | |
Maryanoff et al. | Macrocyclic peptide inhibitors of serine proteases. Convergent total synthesis of cyclotheonamides A and B via a late-stage primary amine intermediate. Study of thrombin inhibition under diverse conditions | |
RU2637924C2 (ru) | Способы синтеза аматоксинового структурного блока и аматоксинов | |
RU2715233C2 (ru) | Способ получения производных азотистого иприта | |
US20220002348A1 (en) | Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors | |
WO2013118823A1 (ja) | セレウリドおよびその誘導体の製造方法、セレウリド製造の為の中間体ならびにセレウリド誘導体 | |
Shao et al. | Synthesis and structure revision of symplocin A | |
Obrecht et al. | Design and synthesis of novel nonpolar host peptides for the determination of the 310‐and α‐helix compatibilities of α‐amino acid buildig blocks: An assessment of α, α‐disubstituted glycines | |
CN108530518A (zh) | 海兔毒素10类似物及其制备方法和应用 | |
Hollósi et al. | β‐Turns in serine‐containing linear and cyclic models | |
US8981049B2 (en) | Aziridine mediated native chemical ligation | |
Dahiya et al. | Synthesis and biological evaluation of a novel series of 2-(2'-isopropyl-5'-methylphenoxy) acetyl amino acids and dipeptides | |
RU2817013C1 (ru) | Способ синтеза циклических депсипептидов | |
KR20200078999A (ko) | 트리펩타이드의 제조방법 | |
Kessler et al. | Peptide Conformation, IX Conformational Studies on Cyclotripeptides Containing N‐Benzyl‐Glycine | |
JP2020529472A (ja) | ペプチド化合物の環化放出関連する出願の相互参照 | |
Makarasen et al. | Synthesis of four lysine-linked cereulide analogues showing ionophoric activity towards potassium cations as lead compounds for emetic toxin-detection by immunoassays | |
CN112159462B (zh) | 柯义巴肽a衍生物及其用途 | |
Ma et al. | Total synthesis and stereochemical reassignment of tasiamide | |
허준성 | Conformationally-Inspired Total Syntheses of Ohmyungsamycins A and B and Structural Revision of Ohmyungsamycin B | |
WO2019219938A1 (en) | Fmoc protected (2s)-2-amino-8-[(1,1-dimethylethoxy)amino]-8-oxo-octanoic acid, (s)-2-amino-8-oxononanoic acid and (s)-2-amino-8-oxodecanoic acid for peptide synthesis | |
Koley et al. | A facile one step synthesis of N-2 substituted 3-phenyliminoisoindolinones from N-(2-carboxybenzoyl)-anthranilic acid and the design of reverse-turn mimetics | |
US20030073721A1 (en) | Peptide beta-strand mimics based on 1,2-dihydro-3(6H)-pyridinone | |
CA2638777A1 (en) | Novel isodipeptide | |
Sureshbabu et al. | HOAt. DCHA as co-coupling agent in the synthesis of peptides employing Fmoc-amino acid chlorides as coupling agents: Application to the synthesis of β-casomorphin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13746354 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013557569 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14377748 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20147022990 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013746354 Country of ref document: EP |